

AI INNOVATIONS IN DRUG DELIVERY AND PHARMACEUTICAL SCIENCES; ADVANCING THERAPY THROUGH TECHNOLOGY



AI

Editors:
Kuldeep Vinchurkar
Sheetal Mane

Bentham Books

AI Innovations in Drug Delivery and Pharmaceutical Sciences; Advancing Therapy through Technology

Edited By

Kuldeep Vinchurkar

*Department of Pharmaceutics and Pharmaceutical
Technology*

Krishna School of Pharmacy and Research

Drs. Kiran and Pallavi Patel Global Univeristy (KPGU)

Varnama, Vadodara, Gujarat-391240, India

&

Sheetal Mane

NMT Gujarati College of Pharmacy, Indore, M.P., India

**AI Innovations in Drug Delivery and Pharmaceutical Sciences;
Advancing Therapy through Technology**

Editors: Kuldeep Vinchurkar and Sheetal Mane

ISBN (Online): 978-981-5305-75-3

ISBN (Print): 978-981-5305-76-0

ISBN (Paperback): 978-981-5305-77-7

© 2024, Bentham Books imprint.

Published by Bentham Science Publishers Pte. Ltd. Singapore. All Rights Reserved.

First published in 2024.

BENTHAM SCIENCE PUBLISHERS LTD.

End User License Agreement (for non-institutional, personal use)

This is an agreement between you and Bentham Science Publishers Ltd. Please read this License Agreement carefully before using the ebook/echapter/ejournal (“**Work**”). Your use of the Work constitutes your agreement to the terms and conditions set forth in this License Agreement. If you do not agree to these terms and conditions then you should not use the Work.

Bentham Science Publishers agrees to grant you a non-exclusive, non-transferable limited license to use the Work subject to and in accordance with the following terms and conditions. This License Agreement is for non-library, personal use only. For a library / institutional / multi user license in respect of the Work, please contact: permission@benthamscience.net.

Usage Rules:

1. All rights reserved: The Work is 1. the subject of copyright and Bentham Science Publishers either owns the Work (and the copyright in it) or is licensed to distribute the Work. You shall not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit the Work or make the Work available for others to do any of the same, in any form or by any means, in whole or in part, in each case without the prior written permission of Bentham Science Publishers, unless stated otherwise in this License Agreement.
2. You may download a copy of the Work on one occasion to one personal computer (including tablet, laptop, desktop, or other such devices). You may make one back-up copy of the Work to avoid losing it.
3. The unauthorised use or distribution of copyrighted or other proprietary content is illegal and could subject you to liability for substantial money damages. You will be liable for any damage resulting from your misuse of the Work or any violation of this License Agreement, including any infringement by you of copyrights or proprietary rights.

Disclaimer:

Bentham Science Publishers does not guarantee that the information in the Work is error-free, or warrant that it will meet your requirements or that access to the Work will be uninterrupted or error-free. The Work is provided "as is" without warranty of any kind, either express or implied or statutory, including, without limitation, implied warranties of merchantability and fitness for a particular purpose. The entire risk as to the results and performance of the Work is assumed by you. No responsibility is assumed by Bentham Science Publishers, its staff, editors and/or authors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products instruction, advertisements or ideas contained in the Work.

Limitation of Liability:

In no event will Bentham Science Publishers, its staff, editors and/or authors, be liable for any damages, including, without limitation, special, incidental and/or consequential damages and/or damages for lost data and/or profits arising out of (whether directly or indirectly) the use or inability to use the Work. The entire liability of Bentham Science Publishers shall be limited to the amount actually paid by you for the Work.

General:

1. Any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims) will be governed by and construed in accordance with the laws of the U.A.E. as applied in the Emirate of Dubai. Each party agrees that the courts of the Emirate of Dubai shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims).
2. Your rights under this License Agreement will automatically terminate without notice and without the

need for a court order if at any point you breach any terms of this License Agreement. In no event will any delay or failure by Bentham Science Publishers in enforcing your compliance with this License Agreement constitute a waiver of any of its rights.

3. You acknowledge that you have read this License Agreement, and agree to be bound by its terms and conditions. To the extent that any other terms and conditions presented on any website of Bentham Science Publishers conflict with, or are inconsistent with, the terms and conditions set out in this License Agreement, you acknowledge that the terms and conditions set out in this License Agreement shall prevail.

Bentham Science Publishers Pte. Ltd.

80 Robinson Road #02-00

Singapore 068898

Singapore

Email: subscriptions@benthamscience.net



CONTENTS

FOREWORD	i
PREFACE	ii
ACKNOWLEDGEMENT	iii
LIST OF CONTRIBUTORS	iv
CHAPTER 1 AN OVERVIEW OF ARTIFICIAL INTELLIGENCE (AI) IN DRUG DELIVERY AND DEVELOPMENT	1
<i>Rakesh E. Mutha, Vishal S. Bagul, Rahul S. Tade c/pf Kuldeep Vinchurkar</i>	
INTRODUCTION	1
HISTORICAL PERSPECTIVE AND EVOLUTION ROLE OF AI IN PHARMACEUTICAL RESEARCH	2
Importance of AI in Drug Delivery and Development	3
FOUNDATIONS OF AI IN DRUG DELIVERY AND DEVELOPMENT	4
Machine Learning Algorithms in Drug Discovery	4
Deep Learning Techniques in Pharmaceutical Research	5
Natural Language Processing (NLP) in Bioinformatics	6
EMERGING ROLE OF AI IN DRUG DELIVERY AND DEVELOPMENT	6
The Drug Discovery Process and its Challenges	6
Use of AI in Target Identification and Validation	7
High-throughput screening and Compound Design AI	8
CASE STUDIES AND EXAMPLES OF SUCCESSFUL DRUG DISCOVERY AI	8
Ebola Inhibitor Discovery by Atomwise	8
Benevolent AI Treatment for Amyotrophic Lateral Sclerosis (ALS)	8
AlphaFold and Protein Folding by DeepMind	9
Drug Repurposing Model by Recursion Pharmaceuticals	9
IBM Watson for Drug Discovery	9
AI-Driven Drug Discovery by Exscientia	9
DRUG FORMULATION AND DELIVERY	10
AI Applications in Drug Formulation and Optimization	10
Personalized Medicine and AI in Dosage Customization	10
Controlled Drug Delivery Systems and AI-Driven Innovations	11
DRUG REPURPOSING AND DRUG-DRUG INTERACTIONS	11
Structure-based Drug Repurposing	12
Genomics-based Drug Repurposing	12
Network Pharmacology-based Drug Repurposing	12
Mechanism-driven Drug Repurposing	13
Predicting Drug Interactions and Adverse Effects	14
PHARMACOKINETICS AND PHARMACODYNAMICS	14
AI in Modeling Drug Pharmacokinetics	15
Predicting Drug Efficacy and Safety Profiles	15
Data-Driven Approaches for Dose Optimization	16
CLINICAL TRIALS AND PATIENT RECRUITMENT	17
AI-Driven Patient Recruitment and Retention Strategies	17
Optimizing Clinical Trial Design AI	18
Regulatory Compliance and Safety	18
CHALLENGES AND PROSPECTS	18
Remaining Challenges in AI-driven Drug Development	19
Ethical, Legal and Regulatory Hurdles	20

The future of AI in Drug Delivery and Development	20
CONCLUSION	21
REFERENCES	21
CHAPTER 2 EXPLORING THE FUNDAMENTAL ASPECTS OF ARTIFICIAL INTELLIGENCE: A COMPREHENSIVE OVERVIEW	28
<i>Singh A., Shaikh Gulfisha, Koshta A. cpf Sheetal Mane</i>	
INTRODUCTION	29
HISTORICAL PERSPECTIVE OF AI	29
SCOPE AND APPLICATIONS OF AI	30
Scope of AI: Unveiling Possibilities	31
Applications of AI: Transforming Sectors	31
KEY COMPONENTS OF AI SYSTEMS	32
TYPES OF AI: NARROW VS. GENERAL	33
Narrow AI (Weak AI)	33
General AI (Strong AI)	33
Distinguishing Factors between Narrow and General AI	34
ETHICAL CONSIDERATIONS IN AI DEVELOPMENT	34
Advocating for Equity and Reducing Prejudice	34
Promoting Transparency	34
Emphasizing the Importance of Privacy	35
Implementing A System of Responsibility	35
Ensuring Security	35
Promoting inclusivity and ensuring accessibility	35
Comprehending the Effects of Social Influence	35
Reducing the Ecological Footprint	36
Guaranteeing the Exercise of Human Authority	36
Enforcing Supervision and Control	36
IMPACT OF AI ON SOCIETY AND ECONOMY	36
Job Automation	36
Current Employment Openings	37
Enhanced Efficacy and Output	37
Advancements and investigation	37
Enhanced Medical Services	37
Improved Customer Experiences	37
Considerations about the Moral and Societal Consequences	38
Challenges in the Field of Cybersecurity	38
Global Contest	38
Education and Workforce Development	38
CHALLENGES AND LIMITATIONS OF AI	39
Opacity	39
AI Systems and Bias	39
Issues on the Protection of Personal Information	39
Ethical Quandaries	39
Lack of Comprehension and Clarity	40
Data Dependency	40
Technological Constraints	40
Threats to Security	40
Employment Disruption	40
Significant Resource Demands	41
Interdisciplinary Collaboration	41

LEGAL AND REGULATORY FRAMEWORK FOR AI	41
Legislation Regarding the Safeguarding of Data and the Protection of Individual's Privacy	41
Ethical Principles and Norms	42
Responsibility and Answerability	42
Legislation Aimed at Safeguarding the Rights and Interests of Consumers	42
Legislation on Discrimination	42
Cybersecurity Regulations	42
Global Collaboration and Regulations	43
Human Rights Considerations	43
Government Supervision and Control	43
Academic Instruction and Skill Development	43
Public Consultation and Engagement	43
INTERDISCIPLINARY NATURE OF AI	44
Mathematics and Statistics	44
Study of Mind and Behavior	44
The Study of Language and the Computational Processing of Human Language	44
Study of Moral Principles and the Fundamental Nature of Knowledge and Existence	44
Legal Regulations and Governmental Guidelines	45
Economics	45
Study of the Structure, Function, and Development of the Nervous System	45
Study of the Natural World and the Interactions Between Living Organisms and their Environment	45
Biomedical Sciences and Healthcare	45
Social Sciences	46
HUMAN-AI COLLABORATION AND INTERACTION	46
Enhancement of Human Capabilities	46
Intuitive User Interfaces	46
Collective Decision-Making	47
Systems that Involve Human Input and Participation	47
Exposition and Clarity	47
Education and Adjustment	47
Ethical Considerations	47
Allocation and Automation of Tasks	47
Supervision of Artificial Intelligence by Humans	48
Feedback loops	48
Emotional intelligence and empathy	48
Academic and instructional preparation	48
AI IN PHARMACEUTICAL FIELD	48
Pharmaceutical Exploration and Advancement	49
Pharmaceutical Reutilization	49
Optimizing Clinical Trials	49
Individualized Medicine	49
Pharmacovigilance	49
Optimizing the Supply Chain	50
Pharmaceutical Pricing and the Ability to Enter the Market	50
Enhancing Patient Involvement and Assistance	50
Diagnostic Image Analysis	51
FUTURE TRENDS AND DEVELOPMENTS IN AI	51
Ongoing Progress in Deep Learning	51
Artificial Intelligence in Edge Computing	51
Artificial Intelligence (AI) in the Field of Healthcare and Life Sciences	52

<i>Artificial Intelligence (AI) Ethics and the concept of Responsible AI</i>	52
Artificial Intelligence-powered Innovation	52
Quantum Computing and Artificial Intelligence	52
Artificial Intelligence in the Field of Cybersecurity	52
Artificial Intelligence for Mitigating Climate Change	53
The Application of Artificial Intelligence in the Field of Education	53
Artificial Intelligence-powered Robotics	53
Artificial Intelligence Governance and Regulation	53
Artificial Intelligence in the Field of Agriculture	53
CONCLUSION: BALANCING PROGRESS AND RESPONSIBILITY IN AI	54
Unparalleled Prospects	54
Ethical Considerations	54
Clarity and Comprehensibility	54
Equitable Progress	55
Continuous Education and Promotion of Awareness	55
Regulation and Governance	55
Principles of Sustainability	55
Collaboration Between Humans and Artificial Intelligence	55
Iterative Learning and Adaptation	55
REFERENCES	56
CHAPTER 3 PROSPECTS FOR THE FUTURE: ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL TECHNOLOGY	62
<i>Pravin S. Admane, Vikas S. Patil cpf Kuldeep Vinchurkar</i>	
INTRODUCTION	63
History of Artificial Intelligence	64
Advantages of AI Technology [8, 10]	67
Disadvantages of AI Technology [8, 10]	68
Classification of Artificial Intelligence [1]	68
<i>Based on the Caliber</i>	68
<i>Based on Presence</i>	68
<i>Based on their Caliber</i>	69
<i>Based on Presence</i>	69
ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL INDUSTRIES [12]	70
ARTIFICIAL INTELLIGENCE IN PHARMACY [12]	71
ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY	71
Target Identification or Drug Screening	72
De Novo Design of Drug Discovery in AI	74
ARTIFICIAL INTELLIGENCE TOOLS [10, 16]	77
Robotic Pharmacy	77
Erica Robot	77
Tug Robots	78
MEDi Robot	78
Berg [16]	78
Artificial Neural Networks [17]	79
Deep Learning Methods [18]	79
Machine Learning Method	79
Machine Learning for Target Identification	80
Machine Learning for Imaging Analysis	80
Machine Learning for Structure-Based Drug Design	80
ARTIFICIAL INTELLIGENCE IN DRUG DELIVERY [14, 19]	80

Solid Dispersion	82
Emulsions and Microemulsions	82
Tablets	82
Multiparticulates	83
Artificial Intelligence in Nanomedicines [20]	83
Artificial Intelligence in Prediction of Toxicity	84
In Product Development	84
Modified Release Tablet	85
AI Approaches in Polypharmacology	85
DISCUSSION	85
FUTURE DIRECTION	86
CONCLUSION	86
REFERENCES	87
CHAPTER 4 ARTIFICIAL INTELLIGENCE IN COMMUNITY AND HOSPITAL PHARMACY	89
<i>Saloni Yadav, Priya Jain, Kuldeep Vinchurkar and Sheetal Mane</i>	
INTRODUCTION	90
OBJECTIVES OF AI	90
COMPONENTS OF AI	91
Neural Networks	91
Intelligent Robots	91
Machine Learning	91
Deep Learning	92
Image Recognition Technology	92
Expert System	93
HISTORY OF ARTIFICIAL INTELLIGENCE	93
From 1970s to 2000s Era	94
From 2000 to 2020s	95
CLASSIFICATION OF AI	96
ROLE OF ARTIFICIAL INTELLIGENCE IN HEALTHCARE	98
ARTIFICIAL INTELLIGENCE IN HOSPITAL AND COMMUNITY PHARMACY	100
CONCLUSION	104
REFERENCES	105
CHAPTER 5 REVOLUTIONIZING PERSONALIZED HEALTHCARE: THE DIVERSE APPLICATIONS OF ARTIFICIAL INTELLIGENCE IN MEDICINE	109
<i>Mihir Y. Parmar, Salaj Khare, Harshkumar Brahmhatt and Mayur Chaurey</i>	
INTRODUCTION	110
ARTIFICIAL INTELLIGENCE	114
PERSONALISED MEDICINE	115
ARTIFICIAL INTELLIGENCE IN MEDICAL SCIENCE	117
ARTIFICIAL INTELLIGENCE IN BIOMEDICAL RESEARCH	120
FUTURE OF PERSONALISED MEDICINE IN AI	122
PERSISTENT DIFFICULTIES IN PERSONALISED MEDICINE AND AI	125
CONCLUDING REMARKS	127
ACKNOWLEDGEMENTS	127
REFERENCES	127
CHAPTER 6 NANOROBOTS AND NANOMEDICINE IN DRUG DELIVERY AND DIAGNOSIS	133

Anupam Mishra, Koushlesh K. Mishra, Sushma Mishra, Rajeev Mishra and Sheetal Mane

INTRODUCTION	134
CLASSIFICATION OF NANOROBOTS	135
ADVANTAGES AND LIMITATIONS OF NANOROBOTICS AS NANOMEDICINE	137
Advantages	137
Limitations	138
MECHANISM OF ACTION	138
APPROACHES IN NANOROBOTICS	138
Biochip	138
Nubots	140
Nanobearing and Nanogears	140
Bacteria-based	140
Open Technology	140
Target Site and their Communication with the Machines	140
APPLICATIONS RELATED TO DIAGNOSIS AND TREATMENT	141
In the Treatment and Diagnosis of Cancer Therapy	141
In the Management of Diabetes	141
In Surgical Procedures	142
As an Artificial Oxygen Carrier	142
Applied as Microbivore (Artificial Phagocyte)	142
Act as Artificial Neurons	143
In the Diagnosis and Detection of Atherosclerosis	143
In Cell Repairing and Lysis	143
In the Detection and Diagnosis of Hemophilia	143
In the Treatment and Diagnosis of Gout	143
In the Treatment and Diagnosis of Kidney Stones	143
In the Treatment and Diagnosis of Cleaning Wounds	144
In the Modification Process in Gene Therapy	144
CONCLUSION AND FUTURE PERSPECTIVES	144
REFERENCES	144

CHAPTER 7 ARTIFICIAL INTELLIGENCE IN HERBAL MEDICINE FORMULATIONS 147

Prashant Kumbhar, Narendra Kumar Pandey, Bimlesh Kumar and Kuldeep Vinchurkar

INTRODUCTION	147
Importance of AI in Ayurveda	149
Development of a Database for Ayurvedic Reports	149
AI in Ayurvedic Research and Innovation	151
Application of AI Tools in Ayurvedic Drug Discovery	152
AI and Toxicological Studies	153
AI in Ayurvedic Product Development	153
Future Directions and Trends: AI and Nanotechnology	156
AI-based Products	157
AI-based Education	158
CONCLUSION	158
REFERENCES	159

CHAPTER 8 ROLE OF ARTIFICIAL INTELLIGENCE IN DRUG PRODUCT DESIGN AND OPTIMIZATION OF PROCESS PARAMETERS 163

Pankaj Kumar Pandey, Manoj Likhariya, Juhi Bhadoria, Kuldeep Vinchurkar and Priya Jain

INTRODUCTION	164
AI: Networks and Tools	166
<i>Significance of AI in Revolutionizing these Processes</i>	169
HISTORY OF ARTIFICIAL INTELLIGENCE	171
Early Adoption in Drug Discovery	171
Molecular Modeling and Virtual Screening	172
Integration of Big Data and Machine Learning	172
Rise of Deep Learning and Neural Networks	172
Automation and High-Throughput Screening	173
Personalized Medicine and Genomic Analysis	173
Pharmaceutical Formulation and Process Optimization	173
FUNDAMENTALS OF ARTIFICIAL INTELLIGENCE	173
AI APPLICATIONS IN DRUG PRODUCT DESIGN	174
OPTIMIZATION OF PROCESS PARAMETERS	176
Drug Design and Discovery	176
Process Optimization	176
Predictive Maintenance	176
Regulatory Compliance	176
Personalized Medicine	176
Real-Time Monitoring and Control	177
Data Analysis and Decision Support	177
Drug Formulation Optimization	177
Quality Control	177
Risk Assessment and Mitigation	177
<i>Drug Discovery and Design</i>	178
<i>Optimization of Formulation and Dosage</i>	178
<i>Process Optimization in Manufacturing</i>	178
<i>Clinical Trial Optimization</i>	179
<i>Post-Market Surveillance</i>	179
CASE STUDIES	179
CHALLENGES AND ETHICAL CONSIDERATIONS	183
Data-related Challenges	183
Multi-objective Optimization	184
Reproducibility	184
Confounders	185
Model Appropriateness	185
Catastrophic Forgetting	185
Language	185
AI Adoption	185
AI in Drug Design	186
Limitations of using AI in Drug Product Design	187
<i>Data Quality and Quantity</i>	187
<i>Interpretability and Transparency</i>	187
<i>Complexity of Biological Systems</i>	187
<i>Limited Generalization</i>	188
<i>Regulatory and Ethical Considerations</i>	188
<i>Computational Resources and Infrastructure</i>	188
FUTURE TRENDS AND DEVELOPMENTS	188
Machine Learning in Drug Discovery	189
Personalized Medicine	189
Automation and Robotics	190

AI in Formulation Development	190
Predictive Maintenance in Manufacturing	190
Quality Control and Assurance	190
Natural Language Processing (NLP) for Literature Mining	190
Digital Twins for Drug Manufacturing	190
Blockchain for Supply Chain Transparency	191
Collaborative Platforms and Open Innovation	191
The Potential Impact of Advancements in AI on the Pharmaceutical Industry	191
<i>Drug Discovery and Development</i>	191
<i>Drug Design and Optimization</i>	191
<i>Clinical Trials</i>	192
<i>Personalized Medicine and Biomarker Discovery</i>	192
<i>Supply Chain and Manufacturing</i>	192
<i>Regulatory Compliance and Drug Safety</i>	192
<i>Drug Pricing and Market Access</i>	192
INTEGRATION OF AI INTO REGULATORY PROCESSES	193
Data Analysis and Processing	193
Risk Assessment	194
Compliance Monitoring	194
Regulatory Reporting and Documentation	194
Fraud Detection and Investigation	194
Decision Support Systems	194
RegTech Solutions	195
Continuous Learning and Adaptation	195
CONCLUSION	195
REFERENCES	196

CHAPTER 9 REGULATORY INSIGHTS INTO ARTIFICIAL INTELLIGENCE IN DRUG DELIVERY AND MEDICAL DEVICES	199
<i>Nayany Sharma, Rekha Bisht, Rupali Sontakke and Kuldeep Vinchurkar</i>	
INTRODUCTION	200
PRESENT CHALLENGES IN PHARMACEUTICALS & THE ROLE OF ARTIFICIAL INTELLIGENCE	201
Supervised AI Learning	202
Unsupervised AI Learning	202
ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY	203
Traditional Vs AI Enabled Approaches	203
<i>Traditional Drug Discovery</i>	203
<i>AI-Enabled Approaches in Drug Discovery</i>	204
<i>Comparison and Impact</i>	204
Application of AI Tools in Drug Discovery	205
<i>Target Identification and Validation</i>	205
<i>Compound Screening and Design</i>	206
Clinical Trial Optimization	207
<i>Predictive Analytics for Patient Selection</i>	207
<i>Real-World Evidence Analysis</i>	207
<i>Adaptive Trial Design</i>	207
Challenges and Limitations of AI in Drug Discovery	208
AI FOR DRUG DELIVERY	208
AI in the Development of Oral Solid Dosage Form	209
<i>AI in Forecasting Drug Release in Formulation</i>	212

<i>AI to Identify Tablet Defects</i>	213
<i>AI to Identify Physicochemical Stability</i>	213
<i>AI to Dissolution Rate Predictions</i>	214
AI in Nanotechnology	214
AI in the Development of Parenteral, Transdermal, and Mucosal Route Products	215
AI in Vaccines and Biological Product Development	217
MEDICAL DEVICES	217
Classification of Medical Devices	218
REGULATORY INSIGHTS FOR MEDICAL DEVICES	218
Product Classification Database	219
Humanitarian Use Device	219
Premarket Approval	219
Post-Market Surveillance (PMS)	220
Medical Device Accessory	220
CONCLUSION	221
ACKNOWLEDGEMENTS	222
REFERENCES	222
CHAPTER 10 ARTIFICIAL INTELLIGENCE IN CLINICAL TRIALS: THE PRESENT SCENARIO AND FUTURE PROSPECTS	229
<i>Praveen Sharma, Leena Pathak, Rohit Doke and Sheetal Mane</i>	
INTRODUCTION TO ARTIFICIAL INTELLIGENCE	230
Evolution of Artificial Intelligence in the Healthcare Sector	230
<i>The 1950s to 1970s: Early Foundations and Digitization</i>	230
<i>The 1970s to 2000s: Pioneering Collaborations and AI Winters</i>	231
<i>From 2000 to 2020: Seminal Advancements in AI</i>	231
Methods of Artificial Intelligence	232
<i>Artificial Intelligence</i>	232
<i>Association Rule Mining</i>	232
<i>Brain-Machine Interface (BMI)</i>	232
<i>Deep Learning</i>	233
<i>Deep Reinforcement Learning (DRL)</i>	233
<i>Human-Machine Interface (HMI)</i>	233
<i>Machine Learning</i>	233
<i>Natural Language Processing</i>	233
<i>Optical Character Recognition (OCR): Natural Language Processing</i>	233
Role of AI in Healthcare and Pharmaceutical	234
INTRODUCTION TO CLINICAL TRIALS AND DRUG DISCOVERY	235
History of Clinical Trials	235
Phases of Clinical Trials	236
Limitations of Traditional Clinical Trials	237
Scope of AI in Clinical Trial Design and Development	238
AI IN CLINICAL TRIALS AND DRUG DISCOVERY	241
Patient Selection	241
Cohort Composition	241
Recruitment Process Assistance	242
Patient Monitoring	244
<i>Patient Adherence Control, Endpoint Detection, and Retention</i>	245
Digital Health Technologies (DHTs) in Trial Conduct	246
AI's Role in Standardizing Medical Imaging for Clinical Trials	246
The Role of AI in Predicting Trial Success	247

The Role of AI in Regulatory and Clinical Data Management	248
CONCLUSION AND FUTURE PROSPECTIVE	250
ACKNOWLEDGEMENTS	251
REFERENCES	251
SUBJECT INDEX	258

FOREWORD

In the vast landscape of pharmaceutical sciences, the confluence of artificial intelligence and drug delivery has emerged as a revolutionary force, redefining the boundaries of therapeutic advancements. "AI Innovations in Drug Delivery and Pharmaceutical Sciences: Advancing Therapy through Technology" stands as a beacon, guiding us through the transformative journey of technology-driven progress in healthcare.

This edited volume brings together a collection of insightful perspectives and groundbreaking research, offering a comprehensive exploration of the symbiotic relationship between artificial intelligence and pharmaceutical sciences. As we navigate the complexities of drug development, personalized medicine, and intelligent drug delivery systems, this book serves as a compass, pointing toward the future of healthcare innovation.

The esteemed editors have curated a diverse array of contributions from leading experts, scholars, and practitioners in the field. Each chapter unfolds a unique facet of the dynamic interplay between AI and pharmaceuticals, providing readers with a nuanced understanding of the challenges, opportunities, and ethical considerations that accompany this technological revolution.

The pace of change in the pharmaceutical landscape demands continuous reflection and collaboration. This volume not only reflects the current state of AI innovations but also serves as a catalyst for future explorations and breakthroughs. It is a testament to the collective commitment to advancing therapy through the seamless integration of technology.

As we embark on this intellectual journey, I commend the editors, contributors, and all those involved in bringing this book to fruition. May "AI Innovations in Drug Delivery and Pharmaceutical Sciences: Advancing Therapy through Technology" inspire and inform, contributing significantly to the ongoing dialogue in this transformative field.

Sudarshan Singh
Office of Research Administration
Chiang Mai University
Chiang Mai 50200, Thailand

PREFACE

Welcome to the forefront of transformative innovation in the intricate realms of drug delivery and pharmaceutical sciences. In this edited volume, "AI Innovations in Drug Delivery and Pharmaceutical Sciences: Advancing Therapy through Technology," we embark on an enlightening exploration into the dynamic intersection of Artificial Intelligence and healthcare. As editors, our goal is to present a compendium of cutting-edge research and insights that underscore the revolutionary impact of AI on the evolution of therapeutic interventions.

The landscape of drug delivery and pharmaceuticals is undergoing a paradigm shift, driven by the fusion of artificial intelligence and technology. This book serves as a collective effort, bringing together diverse perspectives, expertise, and research contributions from leading scholars and practitioners in the field. Each chapter is a testament to the collaborative endeavor to unravel the potential of AI in enhancing drug delivery systems, optimizing treatment regimens, and ultimately advancing the efficacy of therapeutic approaches.

The contributors to this volume are pioneers and thought leaders, each contributing a unique facet to our collective understanding of the synergies between AI and pharmaceutical sciences. From intelligent drug design and personalized medicine to the challenges and ethical considerations in AI applications, this book provides a comprehensive tapestry of the multifaceted impact of technology on the pharmaceutical landscape.

As editors, we are delighted to present this curated collection that reflects the current state of the art in AI innovations in drug delivery and pharmaceutical sciences. We believe that this book will serve as a valuable resource for researchers, students, practitioners, and anyone intrigued by the unfolding narrative of technology-driven advancements in healthcare.

We extend our gratitude to all the contributors for their scholarly endeavors and dedication to pushing the boundaries of knowledge. It is our sincere hope that this book stimulates further exploration, sparks insightful discussions, and inspires future breakthroughs in the ever-evolving field of AI and pharmaceutical sciences.

Enjoy the journey through the pages of "AI Innovations in Drug Delivery and Pharmaceutical Sciences: Advancing Therapy through Technology".

Kuldeep Vinchurkar

Department of Pharmaceutics and Pharmaceutical Technology
Krishna School of Pharmacy and Research
Drs. Kiran and Pallavi Patel Global Univeristy (KPGU)
Varnama, Vadodara, Gujarat-391240, India

&

Sheetal Mane

NMT Gujarati College of Pharmacy
Indore, M.P., India

ACKNOWLEDGEMENT

The compilation of "AI Innovations in Drug Delivery and Pharmaceutical Sciences: Advancing Therapy through Technology" has been a collaborative endeavor shaped by the dedication, expertise, and support of numerous individuals and organizations. As editors, we extend our heartfelt appreciation to all those who have played a significant role in bringing this volume to fruition.

First and foremost, we express our gratitude to the contributing authors whose insightful research and scholarly contributions have enriched the content of this book. Your commitment to advancing the frontiers of knowledge in AI and pharmaceutical sciences has been instrumental in creating a comprehensive and valuable resource.

We extend our sincere thanks to the reviewers who lent their expertise and time to ensure the quality and rigor of the chapters included in this volume. Your constructive feedback has been invaluable in refining the content and maintaining the high standards of this work.

We are grateful to the publishers and editorial team who have worked tirelessly to bring this project to fruition. Your professionalism, guidance, and commitment to excellence have been crucial in shaping the final product.

Our appreciation extends to the academic institutions and research organizations that have provided a conducive environment for the contributors to pursue their innovative research in the field of AI and pharmaceutical sciences.

Last but not least, we thank our families, friends, and colleagues for their unwavering support, encouragement, and understanding throughout the editorial process. Your belief in our vision and commitment to this project have been a source of inspiration.

This book is a collective achievement, and we acknowledge the collaborative efforts of everyone involved. It is our hope that "AI Innovations in Drug Delivery and Pharmaceutical Sciences: Advancing Therapy through Technology" contributes meaningfully to the ongoing discourse in this dynamic field.

Thank you.

List of Contributors

Anupam Mishra	Shri Rama Krishna College of Pharmacy, Satna (M.P), India
Bimlesh Kumar	School of Pharmaceutical Sciences, Lovely Professional University, Punjab-144411, Phagwara, India
Harshkumar Brahmbhatt	Department of Pharmacy, Sumandeep Vidyapeeth Deemed to be University, Vadodara, Gujarat, India
Juhi Bhadoria	Lakshmi Narain College of Pharmacy (RCP), Indore, India
Koshta A.	School of Pharmacy, Devi Ahilya Vishwavidyalaya, Indore, M.P., India
Kuldeep Vinchurkar	Department of Pharmaceutics and Pharmaceutical Technology, Krishna School of Pharmacy and Research, Drs. Kiran and Pallavi Patel Global Univeristy (KPGU), Varnama, Vadodara, Gujarat-391240, India
Koushlesh K. Mishra	Shri Rama Krishna College of Pharmacy, Satna (M.P), India
Leena Pathak	Department of Pharmacology, Jaihind College of Pharmacy, Pune, Maharashtra, India
Mihir Y. Parmar	Krishna School of Pharmacy and Research, KPGU, Vadodara, Gujarat, India
Mayur Chaurey	VNS Group of Institutions, Faculty of Pharmacy, Bhopal, M.P., India
Manoj Likhariya	Lakshmi Narain College of Pharmacy (RCP), Indore, India
Narendra Kumar Pandey	School of Pharmaceutical Sciences, Lovely Professional University, Punjab-144411, Phagwara, India
Nayany Sharma	Department of Pharmacology, Indore institute of Pharmacy, Indore, Madhya Pradesh, India
Praveen Sharma	Department of Pharmacology, Indore institute of Pharmacy, Indore, India
Pravin S. Admane	Gurunanak Technical Institute (Diploma in Pharmacy), Nari Road, Nagpur, MS., India
Priya Jain	Oxford International College, Opposite Pitra Parvat, Gandhi Nagar, Indore, M. P., India
Prashant Kumbhar	School of Pharmaceutical Sciences, Lovely Professional University, Punjab-144411, Phagwara, India
Pankaj Kumar Pandey	Lakshmi Narain College of Pharmacy (RCP), Indore, India
Rakesh E. Mutha	H. R. Patel Institute of Pharmaceutical Education and Research, Shirpur (M. S.), India
Rahul S. Tade	H. R. Patel Institute of Pharmaceutical Education and Research, Shirpur (M. S.), India
Rupali Sontakke	Department of Pharmacology, Faculty of Pharmacy, Medicaps University, Indore, Madhya Pradesh, India
Rajeev Mishra	APS University, Rewa (M.P), India
Rekha Bisht	Department of Pharmacology, Indore institute of Pharmacy, Indore, Madhya Pradesh, India

Rohit Doke	Department of Pharmacology, Jaihind College of Pharmacy, Pune, Maharashtra, India
Singh A.	Modern Institute of Pharmaceutical Sciences, Indore, M.P., India
Shaikh Gulfisha	Modern Institute of Pharmaceutical Sciences, Indore, M.P., India
Sheetal Mane	NMT Gujarati College of Pharmacy, Indore, M.P., India
Saloni Yadav	Acropolis Institute of Pharmaceutical Education & Research, Bypass Road Manglia Square, Indore, M. P., India
Salaj Khare	Krishna School of Pharmacy and Research, KPGU, Vadodara, Gujarat, India
Sushma Mishra	D.H. Waidhan, Singrauli (M.P), India
Vikas S. Patil	Gurunanak Technical Institute (Diploma in Pharmacy), Nari Road, Nagpur, MS., India
Vishal S. Bagul	H. R. Patel Institute of Pharmaceutical Education and Research, Shirpur (M. S.), India

CHAPTER 1

An Overview of Artificial Intelligence (AI) In Drug Delivery and Development

Rakesh E. Mutha¹, Vishal S. Bagul¹, Rahul S. Tade^{1,*} and Kuldeep Vinchurkar²

¹ H. R. Patel Institute of Pharmaceutical Education and Research, Shirpur (M. S.), India

² Department of Pharmaceutics and Pharmaceutical Technology, Krishna School of Pharmacy and Research, Drs. Kiran and Pallavi Patel Global Univeristy (KPGU), Varnama, Vadodara, Gujarat-391240, India

Abstract: The integration of Artificial Intelligence (AI) into pharmaceutical research represents a transformative leap in drug development, addressing the challenges posed by complex diseases and traditional methodologies. In this comprehensive overview, we explore the historical evolution of AI's role in pharmaceutical research and its crucial importance in drug delivery and development. The foundational elements of AI in drug delivery and development are elucidated through an in-depth analysis of machine learning (ML) algorithms, deep learning techniques, and natural language processing in bioinformatics. These form the bedrock for understanding the subsequent chapters that unravel the emerging roles of AI in drug discovery, formulation, and delivery. An insightful examination of drug repurposing and interaction reveals AI-driven strategies, providing new therapeutic avenues. The chapters further unravel AI's impact on pharmacokinetics, pharmacodynamics, and its data-driven approaches for dose optimization. Clinical trials and patient recruitment witness a revolution through AI, optimizing design and ensuring regulatory compliance and safety. This chapter promises a holistic understanding of the symbiotic relationship between AI and pharmaceuticals, offering a roadmap for innovation and efficiency in the pursuit of advanced healthcare solutions.

Keywords: AI-based pharmacokinetics, AI-driven drug development, Artificial intelligence, Artificial neural network, Bioinformatics, Clinical trials, Deep learning, Dose optimization, Dosage customization, Drug discovery.

INTRODUCTION

The integration of artificial intelligence (AI) into pharmaceutical research has ushered in a new era of innovation and efficiency. This burgeoning field repre-

* Corresponding author **Rahul S. Tade:** H. R. Patel Institute of Pharmaceutical Education and Research, Shirpur (M. S.), India; E-mail: taderahul2011@gmail.com

sents a convergence of advanced computational techniques and the intricacies of drug development. As the complexity of disease continues to challenge traditional research methodologies, AI emerges as a transformative force, offering novel solutions and insights. The amalgamation of AI and pharmaceuticals not only expedites the drug discovery process but also enhances precision and efficacy in treatment strategies [1].

The primary motivation behind the incorporation of AI into pharmaceutical research lies in its ability to analyze vast datasets with unprecedented speed and accuracy. Traditional drug discovery methods often face bottlenecks in data processing, limiting the scope and pace of research. AI, equipped with ML algorithms, can discern patterns and correlations within data, accelerating the identification of potential drug candidates and streamlining the initial stages of drug development. This synthesis of computational power and pharmaceutical expertise marks a paradigm shift, allowing researchers to explore a broader landscape of possibilities [2].

HISTORICAL PERSPECTIVE AND EVOLUTION ROLE OF AI IN PHARMACEUTICAL RESEARCH

The historical trajectory of AI in pharmaceutical research is a fascinating narrative of evolution and adaptation. In its nascent stages, AI was primarily employed for basic tasks such as data organization and analysis. However, as computational capabilities advanced, AI found its niche in drug discovery. Early applications focused on the virtual screening of chemical compounds, predicting potential drug candidates with a level of efficiency previously unattainable. Over time, the role of AI in pharmaceutical research has expanded, encompassing molecular modelling, target identification, and even clinical trial optimization [3] (Table 1).

Table 1. Historical overview of ai development in the pharmaceutical field.

Time Period	Discovery/Event	Company/Industry/Research	Significance	Refs.
1950s	Introduction of AI	Alan Turing's work on computation	Laid the theoretical foundation for AI.	[4]
1980s	Expert Systems	MYCIN system for medical diagnosis	A pioneer in using AI for medical decision-making.	[5]
1990s	Genetic Algorithms	Application in drug design and optimization	Introduced evolutionary computation for drug discovery.	[6]
2000s	Data Mining in Genomics	Use of AI for analyzing genomic data	Accelerated gene discovery and understanding of diseases.	[7]

(Table 1) cont....

Time Period	Discovery/Event	Company/Industry/Research	Significance	Refs.
2010s	IBM Watson for Oncology	AI-driven system for cancer treatment recommendations	Personalized treatment options based on patient data.	[8]
2010s	DeepMind's AlphaFold	Predicting protein structures with AI	Revolutionized understanding of molecular biology.	[9]
2010s	Atomwise for Drug Discovery	Virtual screening using AI for drug candidates	Accelerated identification of potential drug compounds.	[10]
2010s	PathAI for Pathology	AI-powered pathology diagnostics	Enhanced accuracy and efficiency in pathology analysis.	[11]
2020s	COVID-19 Drug Discovery	AI models for rapid drug repurposing	The expeditious identification of potential treatments during the pandemic.	[12]
2020s	Synthesis of Drug Molecules	Deep generative models for drug design	Facilitated the generation of novel drug structures.	[13]
2020s	FDA Approval of AI Diagnostic	First approval of an AI-based diagnostic system	A milestone in regulatory acceptance of AI in healthcare.	[14]
2020s	AI in Vaccine Development	Application of AI for vaccine design	Played a role in expediting COVID-19 vaccine development.	[15]

The evolution of AI in pharmaceuticals is not solely technological; it is also a testament to the collaborative efforts between computer scientists, biologists, chemists, and clinicians. Interdisciplinary collaboration has been pivotal in refining AI algorithms to suit the intricate demands of pharmaceutical research. Today, AI-driven platforms not only assist in the identification of potential drug targets but also contribute significantly to the optimization of experimental design, minimizing resource utilization and expediting the transition from bench to bedside [16].

Importance of AI in Drug Delivery and Development

Traditional drug development often employs a one-size-fits-all model, but AI enables the customization of treatments based on genetic, environmental, and lifestyle factors, enhancing therapeutic outcomes. AI has emerged as a transformative force in various industries, and its impact on drug delivery and development within the pharmaceutical sector is particularly noteworthy. The

Exploring the Fundamental Aspects of Artificial Intelligence: A Comprehensive Overview

Singh A.¹, Shaikh Gulfisha^{1*}, Koshta A.² and Sheetal Mane³

¹ Modern Institute of Pharmaceutical Sciences, Indore, M.P., India

² School of Pharmacy, Devi Ahilya Vishwavidyalaya, Indore, M.P., India

³ NMT Gujarati College of Pharmacy Indore, M.P., India

Abstract: Artificial Intelligence (AI) is a revolutionary technology with transformative potential, notably in the pharmaceutical sector. This abstract provides a comprehensive overview of AI's applications in pharmaceuticals, encompassing drug discovery, development, manufacturing, and healthcare. In drug discovery and development, AI expedites candidate identification and enhances safety and efficacy profiling through advanced data analysis, covering genomics, chemical structure, and clinical data. AI enables drug repurposing by unveiling hidden therapeutic connections in existing medications, reducing costs and timelines, and addressing unmet medical needs. Personalized Medicine is another AI-driven frontier, customizing treatment plans based on patient-specific data like genomics and medical history, enhancing treatment effectiveness. In Clinical Trial Optimization, AI streamlines trial design, patient recruitment, and monitoring speeding approval and reducing costs. AI automates drug manufacturing and quality control, ensuring high-quality products and preventing defects. AI aids in regulatory compliance through real-time monitoring and reporting. Ethical and legal considerations include data privacy and bias mitigation, demanding meticulous attention. Data Security is essential, considering sensitive patient data. Robust cybersecurity safeguards data integrity. In conclusion, AI promises to revolutionize the pharmaceutical sector, accelerating drug discovery, improving patient care, and enhancing manufacturing. However, successful implementation hinges on addressing ethical, legal, and security considerations, fostering collaboration among stakeholders and balancing innovation with responsibility. AI helps in enhancing productivity as well as increases the quality control of the products. In pharmaceuticals, AI also may increase the efficacy of the drug discovery process. It reduces the time of the drug discovery journey along with enhanced efficacy and efficiency of the developed products.

Keywords: Artificial Intelligence, Cybersecurity, Clinical data, Drug discovery, Personalized medicine.

* Corresponding author Gulfisha Shaikh: Modern Institute of Pharmaceutical Sciences, Indore, M.P. India; E-mail: gulfishashaikh76@gmail.com

INTRODUCTION

During the past few years, Artificial Intelligence (AI) has evolved as a force that is capable of bringing about significant changes in the fields of technology, industry, and society. The discipline of artificial intelligence (AI), which is a subfield of computer science, has rapidly developed from a theoretical concept to a practical reality with far-reaching ramifications. AI is committed to the creation of intelligent robots that are capable of emulating human-like cognitive functions [1 - 3].

The purpose of this chapter is to delve into its roots, core concepts, and the various applications that continue to revolutionize how we live and work [4]. Through a study of the fundamentals of artificial intelligence, readers will get a deeper understanding of the potentials, problems, and ethical considerations that are associated with this powerful technology [5, 6]. The main objectives of the study of Artificial Intelligence are to understand the uses and significance of AI in the pharmaceutical field starting from drug discovery to the post-marketing surveillance. The aim of this study is to identify the use of AI in enhanced accuracy in target identification.

HISTORICAL PERSPECTIVE OF AI

To comprehend the current status of Artificial Intelligence (AI), it is imperative to explore its historical roots, tracing its evolution from conceptual foundations to the sophisticated systems observable today. The narrative of AI's development is a captivating exploration marked by notable milestones and shifts in paradigm [7].

Early Philosophical Reflections: The origins of AI can be traced back to ancient philosophical musings on thought and reasoning. Early philosophers contemplated the possibility of constructing machines capable of imitating human cognitive processes, laying the groundwork for subsequent discussions on artificial intelligence [8, 9].

Rise of Computing and Formal Logic: The advent of computers in the mid-20th century provided the computational framework necessary for realizing artificial intelligence. Pioneers such as Alan Turing made significant contributions, with Turing's work on formal logic and the Turing Machine becoming foundational concepts in AI development [9 - 11].

Dartmouth Conference (1956): A pivotal moment in the history of AI occurred at the Dartmouth Conference in 1956. Recognized as the birthplace of AI, this event brought together influential figures, including John McCarthy, Marvin Minsky, Allen Newell, and Herbert A. Simon. The conference marked the formal

establishment of AI as a field of study, outlining ambitious goals for creating machines that could replicate human intelligence.

Early AI Programs and Symbolic AI: In the subsequent decades, AI researchers focused on symbolic AI, developing programs capable of manipulating symbols and representing human knowledge. This period witnessed notable achievements, such as the General Problem Solver developed by Allen Newell and Herbert A. Simon [12].

The AI Winter: Despite early successes, the field encountered setbacks and funding declines in the 1970s and 1980s, a period known as the “AI winter.” Unrealistic expectations, technical limitations, and funding challenges led to a temporary slowdown in AI research.

Rise of Machine Learning: The late 20th century witnessed a resurgence in AI research, driven by advancements in machine learning. Techniques such as neural networks gained prominence, contributing to breakthroughs in domains like natural language processing and pattern recognition [13].

Contemporary AI Landscape: In recent decades, AI has become an integral part of daily life, with applications ranging from virtual assistants and recommendation systems to complex decision-making in healthcare and finance [14, 15]. The integration of big data, powerful computing, and advanced algorithms has propelled AI to unprecedented levels of sophistication.

Understanding the historical trajectory of AI provides a foundation for comprehending the challenges and breakthroughs shaping its current landscape. From philosophical reflections to practical implementation, the journey of AI signifies a persistent pursuit of replicating and enhancing human intelligence [16].

So, it is clearly reflected from the history of AI that it is a long journey to reach the current scenario. It was a stepwise process by clearing the limitations of the previous studies and reaching the correct understanding and uses of AI in different perspectives.

SCOPE AND APPLICATIONS OF AI

Artificial Intelligence (AI) stands as a dynamic field with a diverse array of applications, catalyzing transformative changes across numerous industries [17]. This section delves into the far-reaching impact of AI on various domains, presenting both the opportunities and challenges inherent in its widespread adoption.

Prospects for the Future: Artificial Intelligence in Pharmaceutical Technology

Pravin S. Admane^{1,*}, Vikas S. Patil¹ and Kuldeep Vinchurkar²

¹ Gurunanak Technical Institute (Diploma in Pharmacy), Nari Road, Nagpur, MS., India

² Department of Pharmaceutics and Pharmaceutical Technology, Krishna School of Pharmacy and Research, Drs. Kiran and Pallavi Patel Global Univeristy (KPGU), Varnama, Vadodara, Gujarat-391240, India

Abstract: Artificial intelligence is one of the emerging technologies being utilized in various areas in the pharmaceutical sector to optimize different process parameters, which leads to the development of novel drug delivery systems very efficiently. Astonishing evolution in AI technology and machine learning brings out transformational productivity in the formulation, drug discovery, and testing of pharmaceutical dosage forms. Artificial intelligence utilizes various computational tools and engineering technologies to fabricate varying dosage forms with high therapeutic efficacy and precision. AI algorithms efficiently analyze substantial biological data of proteomics and genomics, which allow researchers to find out the target site and also to predict the interactions with potential drug molecules. This phenomenon permits a targeted approach to drug discovery thereby enhancing the probability of effective drug approvals. Artificial Intelligence (AI) allows the development of intelligent modeling, resolving issues, and decision-making to create efficient data handling. Artificial intelligence plays a very crucial role in various pharmaceutical sectors including drug discovery, formulation and development of novel dosage forms, development of new analytical techniques, development of design of experiments, sales and marketing, quality assurance, clinical trials, hospital pharmacy, *etc.* Various AI-based tools like Artificial Neural Networks (ANNs) or Recurrent Neural Networks (RNNs) are successfully utilized in the field of drug discovery and newer drug delivery systems. Several drug discoveries are being made in pharmaceutical fields using AI technology in combination with quantitative structure-property relationship (QSPR) or quantitative structure- activity relationship (QSAR), which support evidence-based accurate and precise results. Additionally, de-novo design is employed to invent significant new drug molecules with the desired quality. AI algorithms are helpful in experimental design, which can accurately determine the pharmacokinetic parameters and toxic effect of drug molecules. They also allow the identification of impurities and the optimization of their concentration in the product to formulate an effective dosage form. AI-based technology can be applied to optimize the drug excipient ratio in the formulation of a new modified drug delivery system inc-

* Corresponding author Pravin S. Admane: Gurunanak Technical Institute (Diploma in Pharmacy), Nari Road, Nagpur, MS., India; E-mail: admanepavin16061987@gmail.com

cluding sustained, delayed, or immediate release formulation. Formulation of personalized medications as per patient's need is one of the novel approaches that can be possible by the utilization of AI tools, leading to more precise rational treatment and improved patient compliance. The content incorporated further highlights more detailed information on AI tools and their wide applications in various pharmaceutical departments including drug discovery, process optimization, designing novel delivery systems, testing, pharmacokinetics/ pharmacodynamics (PK/PD) studies, *etc.*

Keywords: Artificial intelligence, Drug delivery system, Manufacturing of pharmaceutical products, Pharmaceutical field.

INTRODUCTION

Artificial Intelligence is one of the newly developed platforms nowadays used in different sectors. AI utilizes computational tools comprising software and engineering technologies to execute various complex tasks in an automated way in coordination with human intelligence [1]. AI-enabled machines are capable of understanding large volumes of data efficiently in order to identify lacunas in the current traits of any product and to design some procedures to overcome such lacunas, which will be acceptable to the society comprising new trends. The main objective of artificial intelligence is to explicate important information that identifies issues and provides better solutions. AI at present covers many areas including playing intellectual games, proving mathematical and statistical equations, writing articles, driving vehicles in crowded areas, *etc.* Apart from these, AI also plays a significant role in the healthcare system, where it is being utilized to diagnose the root cause of the disease, to plan the best treatment for patients facing chronic diseases like cancer, to be a part of robotic surgery which can help surgeons perform surgeries with more accuracy and minimal fluctuations and facilitate the latest updated information at the time of operation, to tailor personalized treatment as per patient need, and even to prognosticate patient survival rates.

AI technology allows more accurate analyses to perform any task and also to gain accurate interpretation of data using various useful statistical models in combination with computational intelligence [2]. Pharmaceutical Industries are continuously exploring research activities based on AI technology to produce effective and error-free medicines for patient use. Pharmaceutical sector has been utilizing data digitalization processes in the recent past, but there was a failure to produce more complex dosage regimens and thereby, unable to solve more complex clinical problems [3]. This problem brings the application of AI technology in pharmaceutical sectors, as it is able to analyze a large number of data and generate accurate results with increased automation [4]. A wide range of AI applications are being utilized in pharmacy including formulation and

development, drug discovery, testing, and other healthcare applications. The AI tools also make it practicable to determine pharmacokinetic parameters of the drugs, *in vitro-in vivo* studies, personalized dosing, *etc.* AI technology uses a fundamental model of machine learning (ML), which utilizes various algorithms to recognize patterns as per data input. Machine Learning is also known as Deep learning (DL), which has evolved into different Artificial Neural Networks (ANNs) like Convolutional neural networks (CNNs), Deep neural networks (DNNs), and Recurrent neural networks (RNNs). Recurrent neural networks comprise a closed-loop, which has the potential to store and memorize information, like Hopfield networks and Boltzmann constants [5, 6]. On the other hand, convolutional neural networks (CNNs) use image and video processing in case of processing complex brain functions, biological system modelling, sophisticated signal processing, and pattern recognition [7].

Artificial intelligence (AI) has come into view as an evolutionary technology in the field of pharmaceutical sciences over the past few years. As the development of new drugs and dosage forms using conventional technologies is a very complex process associated with high risk and high costs, AI has been used as an extension of work in the development of novel formulations to treat a variety of diseases in a more accurate and précised manner in the consideration of patient-oriented approaches [8]. It also enhances the productivity of pharmaceutical products by reducing the time cycle and cost of development of formulation.

History of Artificial Intelligence

In the year 1943, the first work was done using AI-based technology by Warren McCulloch and Walter Pitts who put forward the model of Artificial Neurons. Later on, most research works have been performed based on AI-based pharmaceutical technology [8]. In 1950, Alan Turing, a mathematician and computer scientist developed a test called “Turing Test” to determine whether a machine can illustrate human intelligence. In 1956, an American computer scientist John McCarthy discussed AI at the Dartmouth conference. Later on, AI-based technology began to be utilized in industry to perform various activities in an efficient manner. The robot was the first industrialist to perform automated Die Casting, joining the assembly line at General Motors. During the period of the 1970s, AI was the first time applied to foster the development of “The Research Resource on Computers in Biomedicine” by Saul Amarel in 1971 at Rutgers University. In 1972, the first humanoid robot was developed in Japan as WABOT-1. Later on, the CASNET model has been developed at Rutgers University. It is a causal associational network, which was officially demonstrated in the meeting at the Academy of Ophthalmology in Las Vegas, Nevada, in 1976. It consists of three separate programs comprising model building, consultation,

CHAPTER 4

Artificial Intelligence in Community and Hospital Pharmacy

Saloni Yadav¹, Priya Jain^{2,*}, Kuldeep Vinchurkar³ and Sheetal Mane⁴

¹ Acropolis Institute of Pharmaceutical Education & Research, Bypass Road Manglia Square, Indore, M. P., India

² Oxford International College, Opposite Pitra Parvat, Gandhi Nagar, Indore, M. P., India

³ Department of Pharmaceutics and Pharmaceutical Technology, Krishna School of Pharmacy and Research, Drs. Kiran and Pallavi Patel Global Univeristy (KPGU), Varnama, Vadodara, Gujarat-391240, India

⁴ NMT Gujarati College of Pharmacy Indore, M.P., India

Abstract: The integration of artificial intelligence (AI) into pharmaceutical research represents a transformative leap in drug development, addressing the challenges posed by complex diseases and traditional methodologies. In this comprehensive overview, we explore the historical evolution of AI's role in pharmaceutical research and its crucial importance in drug delivery and development. The foundational elements of AI in drug delivery and development are elucidated through an in-depth analysis of machine learning (ML) algorithms, deep learning techniques, and natural language processing in bioinformatics. These form the bedrock for understanding the subsequent chapters that unravel the emerging roles of AI in drug discovery, formulation, and delivery. An insightful examination of drug repurposing and interaction reveals AI-driven strategies, providing new therapeutic avenues. The chapters further unravel AI's impact on pharmacokinetics, pharmacodynamics, and its data-driven approaches for dose optimization. Clinical trials and patient recruitment witness a revolution through AI, optimizing design and ensuring regulatory compliance and safety. This chapter promises a holistic understanding of the symbiotic relationship between AI and pharmaceuticals, offering a roadmap for innovation and efficiency in the pursuit of advanced healthcare solutions.

Keywords: Artificial intelligence (AI), AI in healthcare, AI in drug discovery, Community pharmacy, Deep learning, Hospital pharmacy, Machine learning.

* Corresponding author Priya Jain: Oxford International College, Opposite Pitra Parvat, Gandhi Nagar, Indore, M. P., India; E-mail: drpriyajain14@gmail.com

INTRODUCTION

Artificial intelligence (AI) is the amalgamation of diverse intelligent processes and behaviours, formulated through computer models, algorithms, or a collection of guidelines that enable the machine to emulate human cognitive capabilities like learning, problem-solving, and so on [1, 2]. In its most basic form, artificial intelligence (AI) is the science and engineering that builds intelligent computers by programming them to follow algorithms or rules that simulate human cognitive processes like learning and problem-solving [3]. AI systems are capable of acting in a meaningful, intelligent, and adaptive way because they have the capacity to foresee challenges or address them as they emerge [4]. Consequently, artificial intelligence (AI) is a collection of intelligent behaviours and processes produced by computer models and algorithms rather than a single technology. AI has advanced faster recently attributable to improved computational models and algorithms, strong computers, and the availability of vast datasets. This has been particularly relevant for machine learning (ML), natural language processing (NLP), AI voice technologies, AI assistants, and robots [5]. AI is rapidly advancing in the healthcare industry and has a significant impact on automation, disease detection, and clinical decision-making. Artificial Intelligence (AI) presents the potential for further exploration in the realm of pharmaceutical and healthcare research due to its capability to analyze massive amounts of data from multiple modalities [1].

OBJECTIVES OF AI

- ***Expert system development:*** It entails developing intelligent, automated systems that advise users on what to do next.
- ***Human intelligence in computers:*** It is intended to assist computers acquire similar cognitive patterns so they can act like people and take the appropriate actions to deal with challenging circumstances.
- ***Multi-domain applications:*** AI will promote the application of various fields, including healthcare, psychology, natural sciences, ethics, and more.

Medical technology has been completely transformed by artificial intelligence (AI), which is generally defined as the branch of computer science that can handle difficult problems with a variety of applications in fields with a lot of data but little theory. To effectively address complex clinical issues, contemporary medicine has to devise methods for gathering, assessing, and applying the vast amount of information required. The establishment of AI programs intended to assist doctors in diagnosing patients, identifying treatments, and projecting outcomes has been linked to the development of medical AI. They are intended to

aid in the information and knowledge processing required for work that healthcare professionals must regularly complete. Within the field of computer science, Artificial Intelligence (AI) research focuses on the following areas: Neural networks, language recognition, intelligent robotics, machine learning, image recognition, and expert systems [6].

COMPONENTS OF AI

Neural Networks

ANNs are computational tools that are computerized and imitate the nervous system in humans. They are made up of “neurons” or networks of interconnected computer processors, which can process data and represent information in parallel [7]. In 1943, McCulloch and Pitts used basic binary threshold functions to develop the first artificial neuron. Because of their power to generalize, simplify data with independent information, and evaluate non-linear data, they are a highly alluring analytical tool in the field of medicine [8].

Intelligent Robots

An intelligent robot is a machine that possesses the ability to act and make decisions. An intelligent robot's decision-making is influenced by its innate intelligence, which it acquires through machine learning or deep learning, as well as the information it receives from its input sensors while it is operating. In the 1980s, intelligent surgical robots were used. For example, in 1988, PUMA 560 was used in prostate surgery, and in 1985, it was used in neurosurgical biopsies. In 1992, ROBODOC became the first intelligent robot officially acknowledged by the US Food and Drug Administration (FDA). In orthopedic surgery, it was mostly used for hip replacement procedures. Currently, the FDA has approved three different robotic surgical systems, including the ZUES and Da Vinci, an automated endoscopic technique for optimizing robot placement. In urology, orthopaedics, stomatology, and other specialties, intelligent robots are widely used because of their accurate, sophisticated, and secure characteristics [6].

Machine Learning

In the artificial intelligence field of machine learning, it aims to develop algorithms that can automatically learn from experience, improving with each new algorithmic run. The algorithm works by identifying a pattern in the input data and using that pattern to create a model that uses the existing data to predict new data accurately. (Fig. 1) The foundation of machine learning approaches is the discovery of patterns in massive data sets that help forecasts and the decision-making process for diagnosis and therapy planning. Machine learning technique is

CHAPTER 5

Revolutionizing Personalized Healthcare: The Diverse Applications of Artificial Intelligence in Medicine**Mihir Y. Parmar^{1,*}, Salaj Khare¹, Harshkumar Brahmhatt² and Mayur Chaurey³**¹ Krishna School of Pharmacy and Research, KPGU, Vadodara, Gujarat, India² Department of Pharmacy, Sumandeep Vidyapeeth Deemed to be University, Vadodara, Gujarat, India³ VNS Group of Institutions, Faculty of Pharmacy, Bhopal, M.P., India

Abstract: The expansion of high-throughput, data-demanding biomedical research and technologies, like sequencing of DNA, imaging protocols, and wireless health observing manoeuvres, has shaped the need for quality researchers to form plans for detecting, integrating, and interpreting the major amounts of data they generate. Still, a wide variety of mathematical methods have been premeditated to accommodate the ‘large data’ produced by such assays, and familiarities with the use of artificial intelligence (AI) skills advise that they might be chiefly suitable. In total, the solicitation of data-intensive biomedical skills in research education has exposed that clinically humans differ widely at all levels, be it genetic, biochemical, physiological, exposure, and behavioral, especially with respect to disease progression and treatment output. This suggests that there is often a need to shape up, or ‘personalize,’ medicines to the delicate and often complex mechanisms possessed by specific patients. Given how significant data-intensive assays are in revealing appropriate intervention targets and strategies for personalizing medicine, AI can play an interesting role in the expansion of personalized medicine at all major phases of clinical development for human beings and the implementation of new personalized health products, from finding appropriate intervention targets to testing them for their value. The authors describe a number of areas where AI can play a significant role in the growth of personalized medicine, and debate that AI’s ability to spread personalized medicine will depend judgmentally on the ways of loading, accumulating, retrieving and eventually integrating the data that is created. Authors also share their opinions about the limitations of countless AI techniques, as well as pondering areas for further exploration.

* Corresponding author **Mihir Y. Parmar:** Krishna School of Pharmacy and Research, KPGU, Vadodara, Gujarat, India; E-mail: mihirparmar.ksp@kpgu.ac.in

Keywords: AI-based personalized medicine, Artificial Intelligence, Biomedical skills, Clinical data science, Machine learning, Precision medicine.

INTRODUCTION

The delivery of diagnostic, therapeutic, and preventive interventions is predicated on the typical patient one-size-fits-all paradigm in the current healthcare system. Alarming, these broad therapeutic approaches do not sufficiently address the medical needs of a sizable percentage of the population, even if they are feasible to implement [1]. For instance, only 40-60% of patients react to treatment when using medication. Significant inter-individual variability is the cause of the varied medication treatment response rates that are currently extensively reported in the medical literature. It is evident that in order to maximize treatment, a more focused approach to medicine is required, which has led to the development of precision. Although the terms “precision medicine” and “personalised medicine” have been used interchangeably, the term “precision medicine” is currently preferred because it is generally agreed that the term “personalised medicine” may be interpreted incorrectly to mean that preventive and treatment plans are specifically tailored to each individual. Given the magnitude of intra- and inter-individual heterogeneity in drug response as well as the epidemiological, pharmacological, and biological perspectives mentioned above, it is reasonable to infer that individualized treatment at the individual level is more inspirational. Medicine may be revolutionized more realistically by identifying and forecasting subgroups that will respond better or worse [2, 3].

Precision medicine, as opposed to the one-size-fits-all approach, seeks to incorporate each patient's distinct characteristics, including biological data gleaned from imaging, laboratory testing, clinical phenotypes, and medical records, in order to provide a customized diagnosis or treatment plan that has a better chance of working. Patients should anticipate better outcomes in the form of earlier, more accurate diagnoses, more effective treatment, and fewer adverse medication responses. Broader benefits should also include increased healthcare savings and increased economic output. Therefore, a more accurate diagnosis and prognosis than those provided by current clinical and epidemiological recommendations are included in precision medicine. The concept of precision medicine arose from the remarkable achievements in identifying discrete subgroups within specific cancer categories by genome sequencing advancements, which were then successfully targeted as molecular cancers. Precision medicine, as opposed to the one-size-fits-all approach, seeks to incorporate each patient's distinct characteristics, including biological data gleaned from imaging, laboratory testing, clinical phenotypes, and medical records, in order to provide a customized diagnosis or treatment plan that has a better chance of working.

Patients should anticipate better outcomes in the form of earlier, more accurate diagnoses, more effective treatment, and fewer adverse medication responses. Broader benefits should also include increased healthcare savings and increased economic output. Therefore, a more accurate diagnosis and prognosis than those provided by current clinical and epidemiological recommendations are included in precision medicine. The concept of precision medicine arose from the remarkable achievements in identifying discrete subgroups within specific cancer categories by genome sequencing advancements, which were then successfully targeted as molecular cancers [4 - 6].

Precision medicine, in contrast to conventional medicine, is extremely data-intensive and necessitates the flow of health data from individual medical records into various research contexts, such as pharmacovigilance, genomic research, clinical trials, and epidemiological studies, and back into a learning healthcare system that the research findings can be applied to practice [7].

Precision medicine necessitates research in order to improve the generalizability of the interventions. This research applies data gathered during clinical care to real-world clinical outcomes. Large-scale clinical and biomedical data collection is being used to support and expedite research, thanks to the growing understanding of precision medicine's potential and value [8].

The authors of a recent National Academy of Medicine report on the state of artificial intelligence (AI) in healthcare today and in the future noted “unprecedented opportunities” to enhance specialist care and the help AI offers in overcoming human limitations like fatigue and inattention as well as the dangers of machine error. Crucially, the paper points out that although these technologies must be used with caution, there is a lot of promise [9].

AI in healthcare is evolving and progressing quickly thanks to the digitization of health-related data and the quick adoption of new technologies. The application of AI in healthcare may be hampered by issues with multimodal data integration, security, federated learning (which necessitates fundamental advancements in fields like privacy, large-scale machine learning, and distributed optimization), model performance, and bias [10].

The effective integration of AI in healthcare requires adherence to three key principles: shared expertise, analytics and insight, and data and security. Ensuring complete openness and confidence in the data and information needed to train AI systems is synonymous with data security. As the collaboration between humans and AI systems grows, we must have faith in the systems' results.

CHAPTER 6

Nanorobots and Nanomedicine in Drug Delivery and Diagnosis**Anupam Mishra¹, Koushlesh K. Mishra^{1,*}, Sushma Mishra², Rajeev Mishra³ and Sheetal Mane⁴**¹ *Shri Rama Krishna College of Pharmacy, Satna (M.P), India*² *D.H. Waidhan, Singrauli (M.P), India*³ *APS University, Rewa (M.P), India*⁴ *NMT Gujarati College of Pharmacy Indore, M.P., India*

Abstract: Nanobotics is a developing field of nanotechnology that features a nanoscale measurement and can be anticipated to work at the nuclear, atomic, and cellular levels. Nanobotics offers a new frontier in biomedicine, with the potential to transform diagnostics and therapeutics through its unique ability to manipulate biological systems at a nanoscale level. Nanobots have a carbon-based skeleton and a toolkit that includes components such as a hole containing the medicine, a payload, a capacitor, and a microcamera with a tail having the action of swimming. Nanobots are equipped with special sensors that diagnose target particles and molecules inside the body. These sensors can be used to diagnose and treat different imperative infections like cancer, diabetes, atherosclerosis, kidney stones, *etc.* Nanobots can be used to deliver targeted drugs to target areas of the body that are difficult to reach through traditional drug delivery methods such as blood circulation. Nanobots are either powered by exogenous energy (*e.g.*, magnetic field, light, acoustic field, electric field, *etc.*) or endogenous energy (chemical reactions energy). They have been shown to be capable of encapsulating, transporting, and delivering therapeutic content directly to the site of disease, improving the therapeutic effectiveness and reducing systemic adverse reactions of toxic drugs. This chapter covers the following topics: Nano-based nanobots for diagnostics and disease management, types of nanobots, advantages and limitations, robotic approaches in drug delivery, biomedical applications of nanobots, and their future prospects.

Keywords: Approaches, Diagnosis, Drug delivery, Disease management, Nanobotics, Nanobots.

* **Corresponding author Koushlesh K. Mishra:** Shri Rama Krishna College of Pharmacy, Satna (M.P), India; E-mail: koushleshmishra@gmail.com

INTRODUCTION

In the field of pharmaceutical research, drug delivery to target organs, tissues, or cells is always challenging and interesting. Traditional drug delivery methods have not been successful in delivering drugs directly to target organs and achieving maximum therapeutic efficacy with minimal side effects. In traditional drug delivery systems, drug delivery relies on the movement of body fluids as they move through the body. This type of delivery may not treat some diseases, such as stroke or glioblastoma. Existing traditional drug delivery systems deliver drugs directly to the systemic circulation to achieve maximum therapeutic response. Traditional and conventional drug therapy lacks the navigational ability to more precisely deliver drugs to specific target tissues. Delivering drugs to inaccessible tissues in the human body remains a challenge. To achieve targeted delivery of therapeutic agents, drug delivery systems must have autonomous propulsion and controlled navigation. To overcome all these challenges, novel approaches to drug delivery systems are needed [1].

Nanorobotics (Nanobots) is an emerging field that offers great potential for advanced diagnostics and therapeutics. This area has attracted significant interest among research groups due to its autonomous mobility and ability to perform small-scale, complex tasks. Nanorobots can be a great vision for the future of medicine. Nanorobots (Nanobots) meet all these requirements and serve as a promising strategy to solve all these challenges. An ideal nanorobot should have defined target motion and autonomous drug delivery capabilities [2]. Because nanorobots deliver drugs to specific target locations, they must be delivered safely from within the body without causing toxic effects. Nanorobots released from the body's excretory tract must be biodegradable and stable in the external environment. Traditional drug delivery methods paved the way for tumor-targeted treatment, but they relied on increased permeability and retention or ligand-receptor mediated interaction, resulting in a narrow recognition range (0.5 nm) and low targeting effectiveness (0.7%, median). Alternatively, due to their autonomous mobility and navigation in biological media, micro/nanorobots may operate as new "motile-targeting" drug delivery systems to deliver therapeutic payloads, therefore taking a huge step toward successful and safe cancer therapy [3].

Nanobots typically range in size from 1 to 100 nanometers (nm). Nanorobots are specialized devices intended to carry out a specific duty. Nanobots are miniature molecular nanomachines that can travel independently in biological fluids while hauling payload and penetrating. Nanobots are artificial, intelligent submicron objects that travel across space using self-propulsion or an externally controlled propulsion system. Nanobots are created by combining various components of

tiny separate parts or by integrating inorganic components with biological cells or molecules [4]. Nanobots are made of nanomaterials and are programmed to perform a certain task. Nanomaterials are materials with diameters ranging from 1 to 1000 nm. Nanomaterials developed in recent decades have demonstrated potential impacts on medication delivery *via* passive or active targeting mechanisms. Active targeting is mostly based on receptor molecule overexpression, whereas passive targeting is based on the absorption of specific-sized nanomaterials by cancer tissues or lymph nodes. A nanobot is an autonomous, preprogrammed atomic structure [5].

Nanobots are nanoelectromechanical systems with sensing, control, actuation, communication, energy supply, and data transmission properties. The various components of the nanorobot include micro-cameras, electrodes, lasers, ultrasound signal generators, swimming tails, and payloads. Nanobots are nanomachines that connect various interdisciplinary fields of nanotechnology and nanoscience to solve real-time challenges such as targeted drug delivery. Nanobots improve the delivery of drugs and contrast agents to target sites due to their autonomous propulsion and improved navigation through body fluids. Nanorobots are functional molecular devices that can self-assemble, are powered by an external power source, and perform a variety of tasks. These are programmed devices that are inserted through a catheter or injected through a blood vessel and are controlled by an outside surgeon who acts as the on-site surgeon in a variety of complex vascular procedures [6].

Most researchers have chosen intravenous administration as the entry point for nanorobots. Once the nanobot enters the systemic circulation, it is controlled by magnetic fields and field gradients to reach the target site, ultimately activating the nanobot to facilitate drug diffusion across the cell membrane of the target tissue as shown in (Fig. 1). Nanobots can use endogenous fuels such as glucose, urea, and adenosine-5-triphosphate (ATP) for navigation without the need for external devices or propulsion. When developing nanobots, it is important to develop self-sufficient systems that are non-immunogenic and biocompatible, as well as those that utilize fuel resources that are readily available within the body. Nanorobots behave like swarm devices and can be useful for theranostic applications in biomedicine [7].

CLASSIFICATION OF NANOROBOTS

Nanorobots are generally classified into four categories. Nanorobots are broadly categorized into four main types [8], as depicted in (Fig. 2), which provides a detailed classification [8].

CHAPTER 7

Artificial Intelligence in Herbal Medicine Formulations

Prashant Kumbhar¹, Narendra Kumar Pandey¹, Bimlesh Kumar^{1,*} and Kuldeep Vinchurkar²

¹ School of Pharmaceutical Sciences, Lovely Professional University, Punjab-144411, Phagwara, India

² Department of Pharmaceutics and Pharmaceutical Technology, Krishna School of Pharmacy and Research, Drs. Kiran and Pallavi Patel Global Univeristy (KPGU), Varnama, Vadodara, Gujarat-391240, India

Abstract: One promising way to optimize and improve the development of herbal remedies is to incorporate artificial intelligence (AI) methodology into the field of herbal medicinal formulations. AI methods are being used increasingly to analyze large datasets that include traditional knowledge, pharmacological properties, botanical compounds, and therapeutic effects. These methods include machine learning algorithms, neural networks, and natural language processing. These computational tools make it easier to identify bioactive ingredients, anticipate synergistic interactions, and understand the molecular processes that underlie herbal formulations. Furthermore, the process of drug discovery and development can be streamlined by using AI-driven modeling to quickly screen formulations for safety, bioavailability, and efficacy. The combination of AI and herbal medicine works well together to speed up the search for new therapeutic combinations and facilitate comprehension of the complex interactions between phytochemicals and their biological targets. However, issues like algorithm robustness, ethical considerations, and data quality make more research and validation in this emerging field necessary. However, the combination of AI techniques and herbal medicine formulations has great potential to advance evidence-based and personalized healthcare practices.

Keywords: Artificial intelligence, Computational modeling, Herbal medicine, Interactions, Medicinal formulations, Machine learning, Molecular mechanisms.

INTRODUCTION

In the rapidly growing world of healthcare and pharmaceuticals, the integration of artificial intelligence (AI) has ushered in a new era of innovation and efficiency.

* **Corresponding author Bimlesh Kumar:** School of Pharmaceutical Sciences, Lovely Professional University, Punjab-144411, Phagwara, India; E-mail: bimlesh1pharm@gmail.com

One particularly intriguing and promising domain where AI is making significant strides is herbal medicinal formulations [1 - 3]. The core idea of Ayurveda is an understanding of biological system balancing. Ayurveda uses naturally occurring herbs and related techniques to treat illnesses. It is primarily practiced in India and is becoming well-known worldwide. The system of Ayurveda is successful, but it is not widely used. A number of factors have prevented Ayurveda from realizing its full potential, including the lack of emphasis placed on Ayurvedic education and practices, the scant or nonexistent advancements observed, financial constraints, a lack of technical support, and unorganized databases [4 - 6]. Consequently, there is a continuous need to innovate in the field of technology and to efficiently develop knowledge-based systems in order to improve the application of Ayurveda and maximize its advantages [4, 7, 8]. The intersection of traditional herbal medicine with cutting-edge AI technologies holds the potential to revolutionize the way to reach the needs of individuals requiring proper health through healthcare providers. Such approaches play a significant contribution to the speedy delivery of demand to healthcare providers [1, 2]. Assessment of the onset of disease, success of treatment, management of complications, patient care assistance, and research targeted towards rationalized discovery, as well as treatment of the disease, are the five different pillars used in the healthcare systems using AI. These pillars can be a landmark for clinicians, patients, and other healthcare workers [2, 3, 9]. Herbal medicine, with its roots deeply embedded in ancient healing traditions, has long been a source of remedies for various ailments. The vast reservoir of knowledge about the therapeutic properties of herbs, amassed over centuries, is now being harnessed in conjunction with AI to optimize and enhance the formulation of herbal medicines [9]. This synergy between traditional wisdom with modern technology not only preserves the time-honoured principles of herbal medicine but also catapults it into a new era of precision and personalized healthcare [10].

AI has a role in herbal and traditional medicine for the development of formulations. It also extends beyond mere data analysis, synthesis and interpretation of vast datasets, predictive modeling, and the identification of complex patterns within the botanical realm [1 - 3]. Recent reports have provided evidence of the existence of AI where scrutinization of neuroprotective compounds occurs *via* machine learning methods using Xiaoxuming decoction, which affects regulating vascular function and treating stroke recovery [10]. Machine learning algorithms can analyze the chemical composition of herbs, predict their synergism and additive effects, and even suggest novel tentative combinations that may have previously gone unnoticed (Table 1). These unnoticed combinations can be reconsidered for different targets for the treatment of different diseases. This level of computational analysis enables a more nuanced understanding of the intricate relationships between different herbal components,

paving the way for the development of highly targeted and effective formulations [1 - 3].

Table 1. Key features of AI in herbal medicine [7].

Sl. No.	Key Features	AI-driven Results
1	Plant identification	Computerized vision for species recognition
2	Formulation optimization	<ul style="list-style-type: none"> • Machine learning models for optimizing • Enhancement of efficacy
3	Treatment Strategies	<ul style="list-style-type: none"> • Creating individualized herbal treatment • Timeline according to the patient clinical state
4	Interaction prediction	Possible potential interaction between herbals and drugs
5	Quality control and authentication	Ensuring authenticity and quality control
6	Efficacy and toxicity	<ul style="list-style-type: none"> • Identification of models for evaluation • Selection of suitable models • Level of toxicity

Importance of AI in Ayurveda

AI has the power to revolutionize the age-old science of Ayurveda. Possibilities for interdisciplinary research that combines the knowledge bases of AI and Ayurveda can yield ground-breaking results in the diagnosis, treatment, and prevention of illness. Ayurvedic medicine's three core databases—disease, treatment, and human data—are known as the Trisutra. Dosha Prakriti (somatic constitution) and its attributes, Sapta Dhatu (primary body structural components), thirteen Agni types (metabolic/digestive factors), thirteen Srotas (structural or functional body channels), three Mala (body waste products), and Oja (the essence of all seven Dhatu) are included in the first dataset on humans. Medicinal plants with their Rasa (taste), Guna (property/quality/attribute), Virya (potency), and Vipaka (bio-transformed rasa) are included in the second set of Ayurvedic therapeutics. Other procedures include Panchakarma (five internal biocleansing therapies) and Pathyapathya (compatible diet & regimen). The symptoms of the disease come last. Using these three datasets—the Trisutra for AI in Ayurveda—drugs, diet, Dinacharya (daily regimen), and Ritucharya (seasonal regimens) concepts that address chronobiology could be used to diagnose, predict, and prevent disease [1, 4, 11, 12].

Development of a Database for Ayurvedic Reports

Indian medicinal plants and the ways they are used are effective models for treating a variety of common illnesses. The Indian traditional system of medicine, Ayurveda, can be greatly enhanced by classifying Indian medicinal herbs

CHAPTER 8**Role of Artificial Intelligence in Drug Product Design and Optimization of Process Parameters****Pankaj Kumar Pandey^{1,*}, Manoj Likhariya¹, Juhi Bhadoria¹, Kuldeep Vinchurkar² and Priya Jain³**¹ *Lakshmi Narain College of Pharmacy (RCP), Indore, India*² *Department of Pharmaceutics and Pharmaceutical Technology, Krishna School of Pharmacy and Research, Drs. Kiran and Pallavi Patel Global Univeristy (KPGU), Varnama, Vadodara, Gujarat-391240, India*³ *Oxford International College, Gandhi Nagar, Indore, M.P., India*

Abstract: The integration of artificial intelligence (AI) in pharmaceutical research has revolutionized drug product design and the optimization of process parameters, marking a paradigm shift in the traditional drug development paradigm. This abstract explores the multifaceted role of AI in these critical aspects of pharmaceutical manufacturing. The chapter elaborates the significance of AI in revolutionizing processes like drug discovery, formulation optimization, personalized medicine development, predictive analytics, drug design, improved patient outcomes, and many more. In drug product design, AI-driven methodologies have demonstrated unparalleled capabilities in expediting the identification of novel drug candidates and predicting their pharmacokinetic properties. Machine learning algorithms analyze vast datasets, including molecular structures, biological interactions, and clinical trial outcomes, to unravel complex relationships and generate insights that guide rational drug design. This accelerates the discovery process and enhances the efficiency of lead optimization, ultimately reducing the time and costs associated with drug development. Furthermore, AI plays a pivotal role in optimizing process parameters during drug manufacturing. The pharmaceutical industry faces challenges in ensuring the reproducibility, scalability, and cost-effectiveness of production processes. AI algorithms, particularly in combination with process analytical technologies (PAT), enable real-time monitoring and control, ensuring the quality and consistency of drug products. Through iterative learning and adaptive control, AI-driven systems can dynamically optimize manufacturing parameters, minimizing variations and ensuring the robustness of the production process. In conclusion, the incorporation of AI in drug product design and process optimization is transformative, fostering innovation and efficiency in the pharmaceutical industry. As the field continues to evolve, collaborative efforts between computational scientists, chemists, and engineers are

* **Corresponding author Pankaj Kumar Pandey:** Lakshmi Narain College of Pharmacy (RCP), Indore, India; E-mail: pankajpandeycop@gmail.com

essential to harness the full potential of AI, ultimately advancing drug development and improving patient outcomes.

Keywords: Artificial intelligence, Algorithms, Decision making, Drug product design, Human intelligence, Machine learning, Product development, Regulatory process, Speech recognition, Visual perception.

INTRODUCTION

In early definitions, artificial intelligence (AI) was simply defined as “intelligence exhibited by machines.” The intelligence being exhibited was a human-like response to human communication. Today, due to progress in neuroscience, computation, and programming techniques, the focus of AI has shifted to modeling human intelligence, improving computational tools and media, and advancing goal-oriented processing for complex interactive environments. Due to this shift, AI has found application in almost every domain of human experience and now serves a great range of purposes. Its primary value is to quickly, efficiently, and effectively get better results from the purposeful collection and analysis of information. Its secondary value is in the development and application of digital technology to solve problems or render services for commerce, medicine, environmental science, robotics, transportation, communications, and people.

Over the past few years, there has been a dramatic increase in data digitalization in the pharmaceutical sector. However, this digitalization comes with the challenge of acquiring, scrutinizing, and applying that knowledge to solve complex clinical problems. This motivates the use of AI because it can handle large volumes of data with enhanced automation. AI is a technology-based system involving various advanced tools and networks that can mimic human intelligence. At the same time, it does not threaten to replace human physical presence with completely independent decisions for accomplishing specific objectives. Its applications are continuously being extended in the pharmaceutical field, as described in this review. According to the McKinsey Global Institute, the rapid advances in AI-guided automation are likely to completely change the work culture of society.

Drug product design refers to the systematic and creative process of developing a pharmaceutical product that meets the desired therapeutic objectives, as shown in Fig. (1). It involves the formulation of the drug substance into a final dosage form, considering various factors such as the physicochemical properties of the drug, desired route of administration, patient compliance, and stability. The goal of drug

product design is to ensure the delivery of the right dose of the drug, with the appropriate release profile, in a safe and effective manner [1].



Fig. (1). Drug product design through AI.

The objectives of artificial intelligence in drug product design and optimization of process parameters include:

Assessment of AI Techniques: Evaluate the effectiveness and applicability of various AI techniques (such as machine learning, deep learning, and computational modeling) in drug product design and process optimization.

Optimization of Formulation Parameters: Investigate how AI algorithms can optimize formulation parameters (such as drug-excipient ratios, particle size, and dosage form) to enhance drug efficacy, stability, and patient compliance.

Process Parameter Optimization: Determine the potential of AI-driven approaches in optimizing manufacturing process parameters (including temperature, pressure, and reaction time) to improve product quality, yield, and cost-effectiveness.

Comparison with Traditional Methods: Compare the performance of AI-based optimization strategies with traditional experimental methods in terms of efficiency, accuracy, and scalability.

CHAPTER 9

Regulatory Insights into Artificial Intelligence in Drug Delivery and Medical Devices

Nayany Sharma¹, Rekha Bisht^{1*}, Rupali Sontakke² and Kuldeep Vinchurkar³

¹ Department of Pharmacology, Indore institute of Pharmacy, Indore, Madhya Pradesh, India

² Department of Pharmacology, Faculty of Pharmacy, Medicaps University, Indore, Madhya Pradesh, India

³ Department of Pharmaceutics and Pharmaceutical Technology, Krishna School of Pharmacy and Research, Drs. Kiran and Pallavi Patel Global Univeristy (KPGU), Varnama, Vadodara, Gujarat-391240, India

Abstract: The pharmaceutical industry is grappling with challenges that impede the sustainability of drug development programs, primarily due to escalating research and development costs coupled with diminishing efficiency. This chapter explores the potential of leveraging artificial intelligence (AI), particularly machine learning (ML) and its subset, deep learning (DL), to bring about a transformative impact on the drug development process. ML, characterized by its capacity to learn from data with or without explicit programming, holds promise for addressing the complexities inherent in pharmaceutical research. DL, employing artificial neural networks (ANNs) as a multi-objective simultaneous optimization technique, has demonstrated efficacy in optimizing drug delivery systems. AI has the potential to transform drug discovery, clinical trials, drug delivery, and medical devices, emphasizing alignment with regulatory guidelines. However, challenges such as data quality and model complexity limit its transformative impact on medicine delivery and device development.

This chapter is structured into three parts, each addressing a distinct aspect of AI in the pharmaceutical landscape. The first part provides a foundational introduction to AI in the pharmaceutical industry, elucidating its role in overcoming inherent challenges. The second part delves into the diverse applications of AI-based tools and systems, encompassing drug discovery, various drug delivery systems, and the development of medical devices. Finally, the third part of the chapter sheds light on the regulatory challenges associated with AI-based drug delivery and medical device development, offering insights into the evolving regulatory landscape.

Keywords: Artificial intelligence, Drug delivery, Dosage design, Drug development, Deep learning, Drug discovery, Medical devices, Machine learning, Regulatory.

* Corresponding author **Rekha Bisht:** Department of Pharmacology, Indore institute of Pharmacy, Indore, Madhya Pradesh, India; E-mail: rekha_al03@rediffmail.com

INTRODUCTION

The pharmaceutical landscape is witnessing a seismic shift with the integration of Artificial Intelligence (AI). This transformative technology is not just a new player in the field, but a game-changer that is redefining the entire drug discovery and delivery process. Traditionally, the journey from the lab to the pharmacy shelf has been a long and winding road, fraught with uncertainties and high failure rates. However, the advent of AI has infused a sense of optimism into this intricate process. ML algorithms, a subset of AI, have proven to be particularly effective [1]. They swiftly sift through vast datasets comprising biological, chemical, and clinical information, thereby accelerating the identification of potential drug candidates. These algorithms can predict molecular interactions, propose new drug compounds, and optimize existing molecules with an unprecedented level of precision and efficiency. Moreover, AI's prowess extends beyond mere data analysis. It has the uncanny ability to uncover hidden patterns within complex biological systems, thereby redefining target identification and validation [2]. Through advanced analytics and predictive modeling, AI algorithms can pinpoint disease mechanisms, identify therapeutic targets, and predict a molecule's efficacy or adverse effects. This significantly reduces the time and resources required for preclinical research. But the story does not end with drug discovery. AI is also enhancing drug delivery mechanisms. The amalgamation of nanotechnology and AI has opened avenues for precise drug targeting, controlled release, and personalized medicine. These synergistic approaches allow for the design of nanocarriers capable of navigating biological barriers and delivering therapeutics directly to the desired site of action, thereby minimizing side effects and optimizing treatment outcomes [3].

While the potential of AI in revolutionizing drug discovery and delivery is undeniable, it also presents formidable regulatory challenges. The dynamic nature of AI algorithms poses unique hurdles in regulatory oversight, particularly in establishing standardized protocols for validating and approving AI-generated findings. The interpretability of AI-generated insights and ensuring their reproducibility present considerable challenges, as regulatory frameworks traditionally rely on transparent and comprehensible data for assessment. Moreover, ethical considerations loom large in the integration of AI into drug development [4]. Concerns regarding data privacy, algorithm bias, and accountability underscore the need for robust ethical guidelines and governance frameworks to safeguard against potential pitfalls. Striking a balance between fostering innovation and upholding stringent safety and efficacy standards remains a focal point in the regulatory discourse surrounding AI in pharmaceuticals [5].

In conclusion, AI represents a monumental shift in the pharmaceutical landscape, heralding a new era of transformative innovations [6]. As we navigate this rapidly evolving landscape, it is imperative to continually re-evaluate our regulatory frameworks to ensure the safe and efficient deployment of AI-powered solutions. This review discusses the potential of AI in drug development and discovery and aims to provide insights into the regulatory framework and challenges as well [7].

PRESENT CHALLENGES IN PHARMACEUTICALS & THE ROLE OF ARTIFICIAL INTELLIGENCE

The pharmaceutical sector is actively engaged in the exploration of small molecules as part of efforts to enhance product quality and customer satisfaction, leveraging the numerous advantages they offer. The chemical synthesis process is straightforward and cost-effective, resulting in the availability of a variety of stable and potent formulations in the pharmacy sector. Despite these advantages, innovative small molecules encounter challenges in the form of competition from generic counterparts and the complex data requirements associated with launching and conducting clinical trials. In response to these challenges, the biomolecular drug industry is experiencing rapid growth as a means to address the limitations posed by the small size of molecular structures and the inadequate dissemination of research and innovations.

Biomolecules, characterized by their larger size and composition of amino acids, nucleotides, or ribonucleotides, such as insulin and adalimumab, present intricate pharmacokinetic aspects. The industry is exploring new technological advancements to overcome these challenges and address related issues. AI holds significant promise in the realms of drug delivery innovation and discovery. However, it is not without limitations, necessitating human intervention or intellectual input to interpret complex results. Algorithmic bias in AI can result in inactive molecules being identified during docking simulations, highlighting the need for human involvement in decision-making and cross-verification to mitigate such issues [8].

Considering these drawbacks, AI has enormous potential for use. It could take a lot of effort to lessen AI's drawbacks and improve its effectiveness and dependability. AI approach incorporates ML or its subcategories, such as natural language processing and DL. Both supervised and unsupervised learning are possible, and the kind of algorithm used is also very important. While unsupervised classification seeks to establish homogenous groupings based on characteristics, supervised learning makes use of known inputs and results.

CHAPTER 10**Artificial Intelligence in Clinical Trials: The Present Scenario and Future Prospects****Praveen Sharma¹, Leena Pathak², Rohit Doke^{2,*} and Sheetal Mane³**¹ Department of Pharmacology, Indore institute of Pharmacy, Indore, India² Department of Pharmacology, Jaihind College of Pharmacy, Pune, Maharashtra, India³ NMT Gujarati College of Pharmacy Indore, M.P., India

Abstract: The completion of clinical trials represents a critical phase of 10 to 15 years, with 1.5–2.0 billion USD spent during the drug development cycle. This stage not only consumes significant financial resources but also carries the weight of substantial preclinical development costs. The failure of a clinical trial results in a staggering loss ranging from 800 million to 1.4 billion USD, underscoring the high stakes involved in drug development. Two primary contributors to the elevated trial failure rates are suboptimal patient cohort selection and recruiting methods, along with challenges in effectively monitoring patients throughout trials. Remarkably, only one out of every ten compounds entering a clinical trial successfully makes it on the market. AI holds the promise to revolutionize key aspects of clinical trial design, ultimately leading to a substantial increase in trial success rates. By leveraging AI, improvements can be made in patient cohort selection, refining recruitment techniques, and enhancing real-time monitoring during trials. The integration of AI in these pivotal stages of clinical trials offers a pathway to mitigate the financial risks associated with trial failure, fostering a more efficient and effective drug development process. This book chapter delves into the application of AI techniques, including DL, NLP, DeepQA technology, DRL, HMI, and other advanced methodologies in the context of clinical trials. This abstract provides an overview of how AI interventions can reshape the landscape of clinical trials, offering a glimpse into the present scenario and prospects at the intersection of artificial intelligence and drug development.

Keywords: Artificial Intelligence, AI in healthcare, Clinical trials, Cohort composition, Clinical trial automation, Drug development, Deep learning, Machine learning, Medical imaging, Patient selection, Patient monitoring.

* **Corresponding author Rohit Doke:** Department of Pharmacology, Jaihind College of Pharmacy, Pune, Maharashtra, India; Tel:9834156578; E-mail: rohitdoke2853@gmail.com

INTRODUCTION TO ARTIFICIAL INTELLIGENCE

Artificial Intelligence (AI) is the emulation of human intelligence in machines, designed to mimic human-like thinking, learning, and problem-solving abilities through programming. The goal of AI is to create systems capable of doing activities that previously required human intellect, such as visual perception, speech recognition, decision-making, and language translation [1]. AI comprises a variety of technologies, including machine learning (ML), natural language processing (NLP), *etc.* AI has the potential to revolutionize robotics, and has applications in areas ranging from healthcare to autonomous cars and virtual assistants. AI has the potential to revolutionise businesses by enhancing efficiency, improving accuracy, and decreasing human error. It can rapidly evaluate massive amounts of data and provide predictions or recommendations based on patterns and trends that humans may not perceive. Additionally, AI systems can continuously learn and adapt, allowing them to improve their performance over time [2].

In this segment of the chapter, we have explored the historical evolution of AI, delving into its progression over time. Additionally, we have examined the diverse methods and techniques linked to AI and their significance in the realm of medicine and healthcare.

Evolution of Artificial Intelligence in the Healthcare Sector

The historical development of AI in medicine reflects a dynamic journey marked by challenges, breakthroughs, and collaborations. From the early foundations in the 1950s to the AI winter and the subsequent resurgence in the 21st century, AI's role in medicine has evolved significantly. As we stand on the cusp of a new era, the ongoing advancements in AI continue to redefine the landscape of healthcare, offering unprecedented opportunities for personalized medicine, improved diagnostics, and enhanced patient outcomes. The journey from early conceptualization to the present state underscores the potential for AI to revolutionize [3].

The historical development of AI in health systems can be categorized into distinct time periods, each marked by seminal transformations.

The 1950s to 1970s: Early Foundations and Digitization

The early focus of AI was on developing machines capable of making decisions previously exclusive to human cognition. In the 1960s, the introduction of the first industrial robot arm, animate, and the natural language processing system, Eliza, laid the groundwork for future AI applications. Despite the slow adoption in

medicine, this period saw crucial developments in digitizing data, with the creation of PubMed and other tools setting the stage for the growth of AI in biomedicine [4]. ELIZA's foundational work in NLP is mirrored in current AI applications that use NLP to extract relevant information from unstructured data sources. This capability is crucial in clinical trials for identifying eligible participants and generating insights from vast amounts of textual data, thereby speeding up the trial phases and improving data quality.

The 1970s to 2000s: Pioneering Collaborations and AI Winters

The period from the 1970s to the 2000s is often referred to as "AI winter," marked by diminished funding and waning interest in AI. However, collaboration among pioneers persisted, leading to the development of systems like MYCIN, a backward chaining AI system for diagnosing bacterial infections [5]. The foundational work of systems like MYCIN and DXplain is evident in today's advanced AI-driven CDSS. These modern tools assist clinicians in making informed decisions during trials by analyzing vast amounts of patient data and offering evidence-based recommendations, which improve trial outcomes and reduce time-to-market for new therapies. The AI winter did not halt progress entirely, as evidenced by the creation of DXplain, a decision support system was introduced, showcasing AI's potential in generating differential diagnoses based on inputted symptoms. Despite the challenges, this period laid the groundwork for the later resurgence of interest in ML, setting the stage for modern applications of AIM [6].

From 2000 to 2020: Seminal Advancements in AI

The 21st century witnessed significant breakthroughs in AI, with notable advancements from 2000 to 2020. IBM's creation of Watson in 2007, an open-domain question-answer system, demonstrated the potential for AI to compete with humans on a cognitive level [5]. Watson's success on Jeopardy! in 2011 showcased the power of DL and natural language processing. DeepQA technology, employed by Watson, enabled evidence-based clinical decision-making by drawing information from electronic medical records [7]. The use of Watson in identifying RNA-binding proteins altered in amyotrophic lateral sclerosis in 2017 exemplifies the expanding role of AI in biomedical research. The integration of natural language processing into chatbots, such as Siri and Alexa, transforms communication interfaces, enhancing meaningful interactions. DL, a significant advancement in AIM, with the availability of larger datasets and

SUBJECT INDEX

A

- Advancements, genome sequencing 110, 111
- Adverse outcome pathway (AOP) 153
- Agents 33, 76, 101, 186, 233
 - anti-cancer 76
 - constructing software 233
 - hazardous chemotherapy 101
- AI-assisted 100, 125
 - methods 100
 - monitoring 125
- AI-based 3, 7, 62, 64, 70, 78, 99, 100, 113, 157, 188, 214, 215, 250
 - business intelligence tool 113
 - database 215
 - diagnostic system 3
 - drug discovery processes 7
 - medical devices 188
 - PET imaging 99
 - products 157
 - QSAR techniques 100
 - technique 214
 - technology 62, 64, 70, 78, 250
- AI-designed Immuno-Oncology drug 187
- AI-driven innovations in nanotechnology 11
- AI-enabled 63, 96, 127, 153
 - machines 63
 - robots 96
 - services 127
 - technologies 153
- AI-guided automation 164
- AI-powered 50, 175, 243
 - algorithms 175, 243
 - chatbots 50
- Alzheimer's disease 157, 242
- Amyotrophic lateral sclerosis 8
- ANN methodology 155
- Antiviral activity 75
- Applications 119, 135
 - technical 119
 - theranostic 135
- Architecture 79
 - graphical convolutional 79
- Artificial 62, 64, 68, 69, 79, 81, 82, 83, 84, 97, 142, 155, 166, 199, 210, 211, 212, 213, 234
 - narrow intelligence (ANI) 68, 69, 97
 - neural networks (ANNs) 62, 64, 79, 81, 82, 83, 84, 155, 166, 199, 210, 211, 212, 213, 234
 - red blood cells and respirocytes 142
 - super intelligence (ASI) 68, 69, 97
- Artificial intelligence 42, 46, 49, 51, 52, 53, 77, 92, 96, 97, 115, 126, 179, 188
 - agent 97
 - algorithms 51
 - powered robotics 53
 - systems 42, 46, 49, 52, 96, 97, 115
 - technology 92, 126, 188
 - tools 77, 179
- Atherosclerosis 133, 143
- Atherosclerotic injuries 143
- Atomic, natural 140
- Authorities, regulatory 43, 221, 249
- Automate(s) 28, 195
 - compliance processes 195
 - drug manufacturing 28
- Automated 42, 91, 194
 - compliance documentation 194
 - decision-making procedures 42
 - endoscopic technique 91
 - monitoring systems 194
- Automation 46, 47, 48, 50, 53, 67, 74, 85, 90, 170, 173, 177, 190, 247
 - robotic process 50, 190
- Autonomous 31, 48, 67, 134
 - mobility 134
 - vehicles 31, 48, 67
- Ayurvedic 149, 152, 153
 - drug discovery 152
 - product development 153
 - therapeutics 149

B

Bacterial infections 231
Behavior 33, 35, 44, 142, 155, 166, 168, 169,
175, 190, 194, 209, 216
 drug product 166
 macroscopic 209
Big data research paradigm 121
Biochemical activity 73
Biomarker information 207
Biomaterials 138, 217
 designing 217
Biomedical 14, 45, 111, 114, 126
 data collection 111
 fields 14, 126
 Informatics 114
 sciences and healthcare 45
Biomedical skills 109, 110
 data-intensive 109
Biopsy malignancy 115
Biosensors, chemical 141
Block chain technology 191
Blood transfusion products 143
Boltzmann constants 64, 167
BRCA gene 124
Breast cancer prediction system 115
Brownian motions 140
Businesses 45, 46, 54, 55, 104, 179, 185, 186,
230, 250
 industry's 250
 revolutionise 230

C

Cancer 9, 63, 87, 98, 99, 100, 115, 116, 123,
124, 125, 133, 137, 141, 156
 breast 100, 115, 116, 123
 cervical 124
Cardiac arrhythmias 98
Clusters, high-performance computing 188
Coalition against major diseases (CAMD) 242
Code of federal regulations (CFR) 219
Cognitive 34, 168
 flexibility 34
 techniques 168
Colonoscopy 125
Combination nanotherapy 83
Computational 29, 44, 80, 152, 153, 158, 172,
182, 215
 chemistry 182

 fluid dynamics (CFD) 152
 framework 29
 processing 44
 techniques 80, 153, 158, 172
 technologies 215
Computed tomography (CTs) 137, 213, 242,
247, 249
Computer 14, 84, 247
 -aided diagnosis (CAD) 247
 -based techniques 14, 84
Computer vision 44, 112, 150, 190, 213, 242
 algorithms 242
 systems 190
 techniques 213
Computerized vision 149
Convolutional neural networks (CNNs) 64,
79, 95, 123, 166, 167, 181, 205, 232
COVID-19 3, 12, 13
 drug 3
 drug repurposing 12, 13
Crop monitoring 53
Cryo-electron 12
 microscopes 12
 microscopy 12
Crystallization technology 12
Cyber attacks 38

D

Data 63, 118, 247
 augmentation techniques 247
 digitalization processes 63
 -intensive biomedical technologies 118
Databases 9, 49, 65, 85, 94, 183, 184, 206,
215, 243, 248
 electronic medical 65
Datasets, biological information 116
Deep 6, 15, 64, 64, 172, 206, 210, 229, 233
 neural networks (DNNs) 6, 15, 64, 172,
206, 210
 reinforcement learning (DRL) 229, 233
Deep learning (DL) 1, 5, 51, 64, 73, 76, 89,
92, 95, 166, 172, 185, 199, 229, 231,
233
 techniques 5
Delivery systems 10, 134, 175, 190, 209, 216
 designing drug 190
 effective drug 209, 216
 innovative drug 175
 mucosal drug 216

- traditional drug 134
 - Detection 31, 52, 79, 99, 114, 125, 126, 137, 142, 143, 194, 210, 213
 - fraud 31, 194
 - image-based 114
 - threat 31
 - Devices 45, 120, 140, 141, 142, 143, 168, 169, 218, 219, 220, 232, 233, 245, 246
 - constructing 232
 - consumer 218
 - cosmetic 218
 - technological 45
 - video-capturing 246
 - wearable 245, 246
 - wireless health monitoring 120
 - Diabetes 125, 133, 141
 - Diabetic retinopathy 125, 126
 - Digital health 186, 246
 - applications 186
 - technologies (DHTs) 246
 - Digital twin technology 190
 - Disease(s) 2, 5, 8, 9, 13, 49, 65, 78, 80, 101, 124, 125, 127, 133, 141, 148, 149, 182, 191, 205, 237, 246
 - cardiovascular 101, 124, 125
 - heart 101
 - management 133, 141
 - mental 124
 - neurodegenerative 8
 - pathways 49, 191
 - risk prediction 125
 - Disease outbreaks 102, 103, 124
 - infectious 124
 - Disorders 85, 95, 142, 232, 245, 246
 - neurological 232, 246
 - DNA 80, 83, 109, 140, 144
 - molecules 140
 - synthesis 83
 - DNA-based 137, 140
 - activated machines 140
 - nanorobots 137
 - Drug(s) 11, 13, 14, 71, 83, 87, 155, 157, 215, 246
 - adherence 246
 - release kinetics 155, 215
 - repurposing, effective 13
 - resistance activity 71
 - screening, based virtual 87
 - immuno-oncology 157
 - drug interactions (DDIs) 11, 14, 83
 - Drug delivery 62, 63, 81, 134, 175, 199, 208, 209, 211, 215
 - mechanisms 209
 - systems 62, 63, 81, 134, 175, 199, 208, 209, 211, 215
 - Drug design 73, 79, 100
 - algorithms 73, 100
 - process 79
 - Drug development 4, 5, 10, 19, 20, 86, 199, 204, 212, 214, 221, 238, 239
 - procedures 20, 86, 214
 - process 4, 5, 10, 19, 20, 199, 204, 212, 221, 238, 239
 - Drug discovery 1, 2, 4, 5, 7, 8, 9, 10, 28, 62, 71, 72, 73, 74, 86, 87, 171, 173, 182, 199, 205, 208
 - revolutionize 208
 - transform 199, 208
- E**
- Ebola 8
 - infection 8
 - virus 8
 - Electronic health 6, 17, 18, 50, 86, 95, 103, 113, 124, 207, 218, 221
 - information 103
 - records (EHRs) 6, 17, 18, 50, 86, 95, 113, 124, 207, 218, 221
 - Electronic medical records (EMRs) 13, 117, 231, 241, 243
 - Energy 36, 53, 133, 157
 - chemical reactions 133
 - consumption 36, 53
 - Eroom's law 238, 239
- F**
- Finite element method 152
- H**
- Health information technology 119, 120
 - Healthcare 4, 20, 21, 31, 37, 46, 48, 90, 111, 113, 114, 116, 117, 118, 126, 127, 158, 230, 232, 233, 234, 236, 250
 - contemporary 158
 - industry 90, 113, 114, 117, 118, 126, 250
 - management systems 46
 - policymakers 113

Herbal 150, 151, 152
 compounds 151, 152
 medicinal products 152
 product formulation 150
Herbal medicine 147, 148, 149, 158
 traditional 148
Herbs, classifying Indian medicinal 149
High-throughput screening (HTS) 6, 8, 71,
 151, 173, 182, 186, 190, 203
 processes 151
 systems 173
Human 29, 44, 45, 90, 232
 cognitive processes 29, 44, 90, 232
 -computer interaction (HCI) 45
Huntington's illness 124

I

IBM Watson technology 65
Illnesses 98, 117, 124, 125, 148, 149, 156,
 219, 242
 cardiovascular 124
 inflammatory 156
 neurological 242
Immune responses 156
Industries, biomolecular drug 201
Intelligence 33, 48, 68, 93, 97, 98, 112, 114,
 164, 168, 169
 augmented 112, 114
 emotional 48
 natural 168, 169

K

Kidney stones 133, 143
 crush 143

L

Learning 111, 156
 health systems 156
 healthcare system 111
Linear discriminant analysis (LDA) 73, 203,
 212
Lipophilicity 16
Lymphatic transport 155

M

Machine 30, 64, 66, 80, 85, 86, 89, 90, 91, 97,
 98, 105, 121, 164, 165, 173, 199
 intelligence 105, 121
 learning 30, 64, 66, 80, 85, 86, 89, 90, 91,
 97, 98, 164, 165, 173, 199
Machine learning 4, 75, 79, 85, 91, 92, 101,
 103, 113, 121, 122, 147, 148, 151, 152,
 158, 163, 172, 176, 178
 algorithm-based 121
 algorithms 4, 113, 122, 147, 148, 151, 158,
 163, 172, 176, 178
 method 79, 148
 techniques 75, 91, 92, 101, 103
 tools 85, 152
Machines, restricted memory 96
Magnetic resonance imaging (MRI) 123, 137,
 186
Medical 10, 65, 94, 101, 120, 141, 144, 156
 nanorobots 141, 144
 record systems 65, 94, 120
 therapies 101
 treatment 10, 156
Medical imaging 144, 246, 247
 datasets 247
 systems 144
Medication degradation 213
Medicine 77, 78, 124
 cardiovascular 124
 oral 77
 transport 78
Memory networks 181
Mental processes 97
Micropump mechanism 81
Microscopic images 76
Mining techniques 203
Mitigating climate change 53
ML-based approach 84
Moore's Law 239
MRI 218
 devices 218
 machines 218
Multi-objective optimization techniques 191
Multiscale modelling techniques 208

N

Nanotechnology-based imaging techniques
 137

Natural language processing (NLP) 6, 18, 32, 44, 46, 47, 50, 52, 90, 95, 114, 174, 186, 190, 193, 207, 230, 231, 233
Neural network(s) 30, 32, 74, 75, 79, 81, 82, 91, 95, 96, 155, 158, 172, 174, 205, 206
dynamic 82
technologies 172
Neurological diseases 246
Neurons, artificial 64, 87, 91, 98, 143
Neurosurgical biopsies 91
Next-generation sequencing 118, 120, 124
techniques 118
technology 120

O

Obsessive-compulsive disorder (OCD) 10, 157
Organic synthesis planning 76

P

Parkinson's disease 124, 125
Polymer composition 216
Power 2, 6, 9, 21, 69, 91, 96, 97, 105, 127, 149, 196, 208
brain 69
computational 2, 208
Principal component analysis (PCA) 202, 203, 212
Problem-solving 31, 34, 54, 90, 93, 174
effective 54
Properties 75, 79, 84, 135, 178, 181, 182, 184, 186, 189, 191, 202, 206, 209, 212
atomic 75
data transmission 135
drug loading 212
Protein 12, 13, 75, 205
-protein interaction (PPI) 13, 205
structures 12, 75, 205

Q

QSAR technique 73
Quantitative structure-property relationship (QSPR) 62
Quantum machine learning techniques 52

R

Ramifications 38, 45, 215
economic 38, 45
Random forest (RF) 73, 206, 209, 211, 212
technique 209
Randomized clinical trials (RCTs) 237
Recurrent neural networks (RNNs) 62, 64, 75, 155, 166, 167, 181, 205, 206
Reinforcement learning (RL) 16, 33, 79, 181, 233
Retention techniques 17
Revolutionary 31, 85
applications 31
technique 85
Robotic 50, 80, 190
image acquisition 80
process automation (RPA) 50, 190

S

Sectors 20, 36, 37, 40, 47, 63, 65, 69, 86, 185, 195, 218, 234, 248, 251
business 185
clinical 251
medical 65
medical device 218
Sensors 11, 32, 124, 133, 138, 141, 142, 178, 190, 245, 246
acoustic 141
bioreactor 178
chemical 142
smartphone 124
wearable 245, 246
Septic shock 142
Simplified molecular input line entry system (SMILES) 14, 74, 75, 76
Support vector machines (SVM) 73, 151, 206, 211, 212, 213, 214
Surgeries 63, 91
prostate 91
robotic 63

T

Techniques signals 158
Technologies 81, 86, 112, 164, 200, 245
computational 86
digital 164

- microfabrication 81
- microfluidic 81
- transformative 200
- wearable 112, 245
- Telehealth company Medline 104
- Therapeutic 147, 151, 204, 236
 - effects 147, 151, 204
 - techniques 236
- Tomography 12, 137, 218
 - computed 137
 - machines 218
- Toxicity 74, 80, 84, 137, 138, 149, 152, 153, 184, 189, 191
 - chemical 153
- Tumor(s) 122, 134, 157
 - penetrating peptide 157
 - secondary brain 122
 - targeted treatment 134
- Tumor cells 83, 125
 - circulating 125
- Turing 29, 64, 66, 93
 - machine 29
 - test 64, 66, 93

V

- Virtual screening 2, 6, 12, 49, 73, 151, 169, 172, 181, 195, 204, 207
 - ligands 12
 - methods 151
- Vision 134, 156, 233, 234
 - computational 233, 234
 - rehabilitation 156

W

- Watson 9, 38, 231
 - for drug discovery 9
 - in identifying RNA-binding proteins 231
- Workforce development 38

X

- X-ray tomography 213



Kuldeep Vinchurkar

Prof. Kuldeep Vinchurkar has more than 11 years of research and teaching experience at both undergraduate and postgraduate levels. He is a leading scientist and academician. He did his post-graduation from Rashtrasant Tukadoji Maharaj Nagpur University, Nagpur (M.H) and completed a Ph.D. from School of Pharmacy, Devi Ahilya Vishwavidyalaya, Indore (M.P). He has supervised more than 15 M. Pharm research projects. He attended several national and international conferences organized in pharmaceutical field. He has over 35 research and review publications to his credit, 07 national and international patents granted, 05 national books on pharmaceutical sciences. He is a life member of many professional societies as well as a reviewer of many international and national journals. He has received a number of awards, such as "Outstanding Assistant Professor" award in the pharmaceuticals category, "Young Scientist Award" in the International conference of IPGA, COFPRI-2023, at university cultural center, etc. His research interest is 3D printing, artificial intelligence (AI), novel drug delivery systems especially gastroretentive drug delivery.



Sheetal Mane

Prof. Sheetal Mane completed Ph.D. from School of Pharmacy, Devi Ahilya Vishwavidyalaya in 2024. She has 09 years of teaching experience and one year of industrial experience in the QC department of Wockhardt LTD, Aurangabad. Her research interest is novel drug delivery systems. She has published and presented 27 research and review papers in reputed journals and conferences. She is a book editor of Springer, Apple CRC Press and scrivener, etc. and has published 12 book chapters in reputed. Presently, she is working as associate professor at Shri Gujarati Samaj College of Pharmacy, Indore (M.P).